TRICYCLIC COMPOUNDS AND METHOD OF TREATING HERPES VIRUS

Abstract: The present invention provides a compound of the formula (I) and pharmaceutically acceptable salts having useful antiviral activity against viruses of the herpes family. In said formula, X = O, (CH2)m, S, SO, SO2, NH, NR8 or a chemical bond; Y = O, (CH2)m, S, SO, SO2, NH, NR8; Z = NH, O, NR8, S, SO, SO2. The remaining substituents are described in the specification.

Description: TRICYCLIC COMPOUNDS AND METHOD OF TREATING HERPES VIRUS FIELD OF THE INVENTION The present invention relates to compounds possessing antiviral activity against viruses of the herpes family, or a composition containing them. These compounds provide a method for treating herpes viral infections, including condition caused by herpes simplex I such as cold sores, herpes simplex II such as genital herpes, as well as shingles caused by herpes zoster and infections caused by cytomegalovirus, Epstein Barr Virus. BACKGROUND OF THE INVENTION Various subfamilies of herpes viruses (Herpes viridae) exist: α-herpesvirinae, β-herpesvirinae, γ-herpesvirinae and cercopithecing Herpes virus I (B virus); some specific viruses are: Herpes simplex virus-1 (HSV-1), Herpes simplex virus-2 (HSV- 2), Cytomegalovirus (CMV), Varicella Zoster virus (VZV), Epstein-Barr virus (EBV), human herpes virus-6 (HHV-6), human herpes virus-7 (HHV-7), human herpes virus-8 (HHV) as well as others which may not yet be defined. The incidence of infections by Herpes simplex virus is very high throughout the world. Serological studies showed that herpes viral infections affect a substantial percentage of the population. Reactivation of herpes virus infections may lead to recurrent infections. The risk of severe diseases increases with decreasing immunocompetence of the host. There is a pressing need for improved therapy for treating this disease. Currently, exclusive of vaccines, treatment involves primarily nucleoside drugs such as acyclovir, which target thymidine kinase and suffer from . development of resistance. SUMMARY OF THE INVENTION The present invention provides a compound of the formula and its pharmaceutically acceptable salts, or the compound and its pharmaceutical composition having useful antiviral activity against viruses of the herpes family. I wherein: X = O, (CH 2 ) m , S, SO, SO 2 , NH, N s or a chemical bond; Y = O, (CH 2 ) m , S, SO, SO 2 , NH, NR 8 ; Z = N, NH, O, NHRs, NRg, S, SO, SO 2 ; n = an integer of from 0 to 2; m = an integer of 1,2, or 3; Ri, R 2 , R 3 , R^ R 5 independently are hydrogen, halogen, hydroxyl, amino, mono or dialkylamino, cyano, nitro, alkyl groups (1-6 carbon atoms), alkoxy groups (1-6 carbon atoms), CF 3 , OCF 3 , aminoalkyl (1-6 carbon atoms), aminoaryl, Oaryl, or a heterocyclic ring having 5-7 atoms with 1-4 hetero atoms of N, O or S; Ar = phenyl, substituted phenyl, benzoheterocyclic ring, substituted benzoheterocyclic ring, heterocyclic ring, or substituted heterocyclic ring, which have substitutions R; or R ; Rδ and R are independently hydrogen, alkyl group (1-6 carbon atoms), cycloalkyl (3- 12 carbon atoms), halogen, alkoxy, CF 3 , aminoalkyl (1-6 carbon atoms), aminoaryl, or a heterocyclic ring of from 5-7 atoms with 1-4 heteroatoms of N, O or S; Re and R may also form a ring, optionally cycloalkyl or aryl or substituted aryl; Rs is hydrogen, alkyl (1-6 carbon atoms), cycloalkyl (3-12 carbon atoms), phenyl or substituted phenyl wherein the substituents are as defined above. The invention also provides for a pharmaceutical composition for the treatment of infection or disease caused by a virus, optionally a Herpes virus which comprises an amount of the compound of Claim 1 sufficient to provide an antivirally effective dosage of the compound of Formula I and a pharmaceutically effective carrier. The invention also provides for a method of treatment of infection or disease caused by a virus, optionally a Herpes virus which comprises administering to a subject in need of such treatment an effective antivirally dosage ofa composition of formula I. DESCRIPTION OF PREFERRED EMBODIMENTS The present invention pertains to anti viral compounds. Preferred compounds are as follows: One preferred compound is: Another preferred compound is: Another preferred compound is: IV Another preferred compound is: Another preferred compound is: VI Another preferred compound is: substituted vπ Another preferred compound is: vm The term "alkyl" means a straight or branched hydrocarbon radical having from 1 to 12 carbon atoms unless otherwise specified and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, undecyl, and dodecyl. The alkyl group may be unsubstituted or independently substituted by from 1 to 3 substituents selected fromF, CI, Br, I, OH, NH 2 , SH, CN, NO 2 , OCH 3 , OCH 2 CH 2 OH, NHCH 3 , or N(CH 3 ) 2 . The term "cycloalkyl" means a hydrocarbon ring, which contains from 3 to 12 carbon atoms unless otherwise specified, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and adamantyl. Where possible, the cycloalkyl group may contain double bonds. The cycloalkyl ring may be unsubstituted or substituted by from 1 to 3 substituents selected from alkyl, cycloalkyl, alkoxy, thioalkoxy all as defined herein, hydroxy, thiol, nitro, halogen, amino, formyl, carboxyl, nitrile, -NH-CO-R, -CO-NHR-, -CO 2 R, -COR, aryl, or heteroaryl wherein alkyl (R), aryl, and heteroaryl are defined as herein. The term "alkoxy" having 1-6 carbon atoms means a Ci-C6 alkyl-O- group or radical wherein Ci-C 6 alkyl has the meaning as defined above. Illustrative examples ofa straight or branched alkoxy group or radical having from 1 to 6 carbon atoms, also known as a Ci - C 6 alkoxy, include methoxy, ethoxy, 1-propoxy, 2-propoxy, 1- butoxy, 2-butoxy, 2-methyl- 1-propoxy, and 1,1-dimethylethoxy, 1-pentoxy, 2- pentoxy, 3-pentoxy, 2,2-dimethylpropoxy, 1-hexoxy, 2-hexoxy, 3-hexoxy, and 4- methyl- 1 -pentoxy . The term "thioalkoxy" having 1-6 carbon atoms means a Cι-C 6 alkyl-S- group or radical wherein Ci-Cβ alkyl has the meaning as defined above. Illustrative examples ofa straight or branched thioalkoxy group or radical having from 1 to 6 carbon atoms, also known as a Ci - C 6 thioalkoxy, include methylthio, ethylthio, 1- propylthio, 2-propylthio, 1-butylthio and 2-butylthio, 1-pentylthio, 2-pentylthio, 3- pentylthio, 2,2-dimethylpropylthio, 1-hexylthio, 2-hexylthio, 3-hexylthio, and 4- methyl- 1 -p entylthio . The term "aryl" means an aromatic carbocyclic ring having from 6 to 10 carbon atoms. Illustrative examples of an aryl group or radical include phenyl, 1- naphthyl, and 2-napthyl. The aryl group may be unsubstituted or independently substituted by from 1 to 3 substituents selected, unless otherwise specified, from F, CI Br, I, OH, NH 2 , SH, CN, NO 2 , OCH 3 , OCH 2 CH 2 OH, NHCH 3 , orN(CH 3 ) 2 . The term "Oaryl" means an aryl-O- group or radical wherein aryl has the meaning as defined above. Illustrative examples of an Oaryl group or radical include phenoxy, 1-naphthyloxy, and 2-napthyloxy. Oaryl groups may be unsubstituted or independently substituted by from 1 to 3 substituents selected, unless otherwise specified, fromF, CI, Br, I, OH, NH 2 , SH, CN, NO 2 , OCH 3 , OCH 2 CH 2 OH, NHCH 3 , orN(CH 3 ) 2 . The term "halogen" means bromine, chlorine, fluorine or iodine. The term "monoalkylamino" means an NH-alkyl group or radical wherein alkyl has the meaning as defined abve. The term "dialkylamino" means an N-(alkyl) 2 group or radical wherein alkyl has the meaning as defined abve. The term "aminoalkyl" having 1-6 carbon atoms means an H 2 N-(Cι-C6 alkyl)- group or radical wherein Ci-C 6 alkyl has the meaning as defined above. The aminoalkyl group is a substituted Cι-C 6 alkyl group or radical containing at least one substituent which is NH 2 . The term "aminoaryl" means anH 2 N-aryl- group or radical wherein aryl has the meaning as defined above. The aminoaryl group is a substituted aryl group or radical containing at least one substituent which is NH 2 . The term "carbocycle" means cycloalkyl as defined above. The term "heteroatom" means a nitrogen, sulfur, or oxygen. The term "heterocycle" means a heterocyclic radical which are 5-7 atoms having 1-4 heteroatoms and are selected from: fϊtran, pyrrole, thiophene, oxazole, isoxazole, thiazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, piperazine, piperidine, morpholine, thiomorpholine, oxolane, dioxane, sulfolane, unsubstituted or substituted by 1 to 2 substituents selected from alkyl as defined above. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO2 groups are also included. The term "benzoheterocyclic ring" ("fused heterocycle") refers to a heterocycle that is adjoined at two consecutive positions with a phenyl ring or another heterocycle. such rings may include 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7~benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl. Some of the compounds of Formula I are capable of further forming pharmaceutically acceptable acid-addition and/or base salts. All of these forms are within the scope of the present invention. Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihyrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M., et al., "Pharmaceutical Salts," Journal of ' Pharmaceutical Science, 1977;66:1-19. The acid addition salt of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are ,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge, supra., 1977). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof. Configuration drawn is most preferred. The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I. For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration. For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted, and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or, synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents. Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 100 mg preferably 0.5 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents. In therapeutic use as antagonists of a virus, as agents for the treatment of infections caused by a virus or as agents for the treatment of diseases due to a virus, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily. A daily dose range of about 0.01-mg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired. General procedure 1 (for Singleton synthesis): Reductive amination of aryl amines with aldehydes or ketones. Reagent 2 (1 eq.) was taken in a solvent (dichloromethane, 1,2-dichloroethane or tetrahydrofuran or diethyl ether) and to it reagent 1 (1 to 1.2 eq.) was added. To this solution cooled at 0°C was added a reducing agent (sodium cyanoborohydride or sodium triacetoxyborohydride) (1 to 2 eq.). To it a drop of acetic acid was added and kept under stirring at room temperature for 6 to 24 hours. The excess hydride was quenched by adding methanol. The reaction mixture was diluted with ethyl acetate and washed with saturated ammonium chloride solution, aqueous sodium bisulfite and brine; dried over anhydrous magnesium sulfuate or sodium sulphate. Organic layer was concentrated and crude product was purified by flash silica gel chromatography to afford the final product. The products were characterized by spectral data. The compounds synthesized using this procedure are shown in Table 4. General procedure 2 for multiple, simultaneous solution phase synthesis (combinatorial chemistry synthesis): To a 2-dram glass vial were added, by Tecan liquid handling robot, a solution of reagent 2 (0.05mmol) in trimethyl orthoformate (0.2ml) followed by reagent 1 (0.05mmol) in trimethyl orthoformate (0.2ml). The vial was capped and the reaction mixture was shaken at room temperature for 18 hours (overnight), then concentrated to dryness. To each vial was added, by Tecan™ liquid handling robot, 1,2- dichloroethane (1ml). Solid sodium triacetoxyborohydride (~23mg) was added manually to each vial. A a solution of acetic acid (0.05mmol) in dichloroethane (0.05ml) was added to each vial by Tecan™ liquid handling robot. The vial was again capped and the reaction mixture was shaken at room temperature for 18 hours (overnight). To the reaction mixture was added, by Tecan liquid handling robot, methanol (1ml). The reaction mixture was then transferred, by Tecan liquid handling robot, to be prewashed (That is washed with methanol (2ml) and dichloroethane (1ml)) BAKERBOND spe™ Aromatic Sulfonic Acid (SO 3 H) disposable Extraction Columns. The columns were allowed to drain and then washed with methanol (2xlml) these solvents were discarded. The desired product was eluted from the column using a solution of 2M ammonia in methanol (3x1 ml) and concentrated to dryness in a tared 2-dram vial. The product was analyzed by LCMS (liquid chromotography mass spec). General procedure 3 for multiple, simultaneous solution phase synthesis (combinatorial Chemistry synthesis): To a 2-dram glass vial were added, by Tecan™ liquid handling robot, a solution of reagent 2 (0.05mmol) in N,N-dimethylformamide (0.1ml) followed by reagent 1 (0.05mmol) in N,N-dimethylformamide (0.1ml). Each vial was treated with trimethylorthoformate (0.2ml) by Tecan™ liquid handling robot. The vial was capped and the reaction mixture was shaken at room temperature for 18 hours (overnight), then concentrated to dryness. To each vial was added, by Tecan™ liquid handling robot, 1,2-dichloroethane (1ml). Solid sodium triacetoxyborohydride (~23mg) was added manually to each vial. A solution of acetic acid (0.05mmol) in 1,2- dichloroethane (0.05ml) was added to each vial by Tecan™ liquid handling robot. The vial was again capped and the reaction mixture was shaken at room temperature for 18 hours (overnight). To the reaction mixture was added, by Tecan™ liquid handling robot, methanol (1ml). The reaction mixture was then transferred, by Tecan™ liquid handling robot, to be prewashed (That is washed with methanol (2ml) and 1,2-dichloroethane (1ml)) BAKERBOND spe™ Aromatic Sulfonic Acid (SO 3 H) disposable Extraction Columns. The columns were allowed to drain and then washed with methanol (2xlml) these solvents were discarded. The desired product was eluted from the column using a solution of 2M ammonia in methanol (3xlml) and concentrated to dryness in a tared 2-dram vial. The product was analyzed by LCMS (liquid chromatography mass spec). General procedure 4 for multiple, simultaneous solution phase synthesis (combinatorial Chemistry synthesis): To a 2-dram glass vial were added, by Tecan™ liquid handling robot, a solution of reagent 2 (0.05mmol) in methanol (0.2ml) followed by reagent 1 (0.2mmol) in methanol (0.2ml). To each vial was added, by Tecan™ liquid handling robot, a IN solution of sodium cyanoborohydride in methanol (0.2ml) and a 10% acetic acid in methanol (0.05ml) solution. The vial was capped and the reaction mixture was shaken at room temperature for 18 hours (overnight), then concentrated to dryness. The vial was again capped and the reaction mixture was shaken at room temperature for 18 hours (overnight). To the reaction mixture was added, by Tecan™ liquid handling robot, methanol (1ml). The reaction mixture was then transferred, by Tecan™ liquid handling robot, to be prewashed (That is washed with methanol (2ml) and 1,2- dichloroethane (1ml)) BAKERBOND spe™ Aromatic Sulfonic Acid (SO 3 H) disposable Extraction Columns. The columns were allowed to drain and then washed with methanol (2xlml) these solvents were discarded. The desired product was eluted from the column using a solution of 2M ammonia in methanol (3xlml) and concentrated to dryness in a tared 2-dram vial. The product was analyzed by LCMS (liquid chromatography mass spec). General procedure 5 for multiple, simultaneous solution phase synthesis (combinatorial Chemistry synthesis): To a 2-dram glass vial were added, by Tecan™ liquid handling robot, a solution of reagent 2 (0.05mmol) in 1,2-dichloroethane (0.2ml) followed by reagent 1 (0.15mmol) in 1,2-dichloroethane (0.1ml). To each vial solid sodium triacetoxyborohydride (~25mg) was added manually. A solution of acetic acid (0.05mmol) in 1,2-dichloroethane (0.05ml) was added to each vial by Tecan™ liquid handling robot. The vial was capped and the reaction mixture was shaken at room temperature for 18 hours (overnight). To the reaction mixture was added, by Tecan™ liquid handling robot, methanol (1ml). The reaction mixture was then transferred, by Tecan™ liquid handling robot, to be prewashed (washed with methanol (2ml) and 1,2-dichloroethane (1ml)) BAKERBOND spe™ Aromatic Sulfonic Acid (SO 3 H) disposable Extraction Columns. The columns were allowed to drain and then washed with methanol (2xlml) these solvents were discarded. The desired product was eluted from the column using a solution of 2M ammonia in methanol (3xlml) and concentrated to dryness in a tared 2-dram vial. The product was analyzed by LCMS (liquid chromatography mass spec). General procedure 6 for multiple, simultaneous solution phase synthesis (combinatorial Chemistry synthesis): To a 2-dram glass vial were added, by Tecan™ liquid handling robot, a solution of reagent 2 (0.05mmol) in methanol (0.2ml) followed by reagent 1 (0.15mmol) in methanol (0.1ml). To each vial was added a IN solution of sodium cyanoborohydride in methanol (0.1ml) and a 10% acetic acid in methanol solution (0.05ml). The vial was capped and the reaction mixture was shaken at room temperature for 18 hours (overnight). To the reaction mixture was added, by Tecan™ liquid handling robot, methanol (1ml). The reaction mixture was then transferred, by Tecan™ liquid handling robot, to be prewashed (washed with methanol (2ml) and 1,2-dichloroethane (1ml)) BAKERBOND spe™ Aromatic Sulfonic Acid (SO 3 H) disposable Extraction Columns. The columns were allowed to drain and then washed with methanol (2xlml) these solvents were discarded. The desired product was eluted from the column using a solution of 2M ammonia in methanol (3xlml) and concentrated to dryness in a tared 2-dram vial. The product was analyzed by LCMS (liquid chromatography mass spec). General procedure 7 for multiple, simultaneous solution phase synthesis (combinatorial Chemistry synthesis): To a 2-dram glass vial were added, by Tecan™ liquid handling robot, a solution of reagent 2 (0.05mmol) followed by reagent 1 in N,N-dimethylformamide (0.32ml) or methanol (0.2ml). The vials were then concentrated overnight to dryness. Each vial was treated by Tecan™ liquid handling robot with reagent 1 (0.15mmol) in methanol (0.1ml) and methanol (0.2ml). To each vial was added a IN solution of sodium cyanoborohydride in methanol (0.1ml) and a 10% acetic acid in methanol solution (0.05ml). The vial was capped and the reaction mixture was shaken at room temperature for 18 hours (overnight). To the reaction mixture was added, by Tecan™ liquid handling robot, methanol (1ml). The reaction mixture was then transferred, by Tecan™ liquid handling robot, to be prewashed (washed with methanol (2ml) and 1,2-dichloroethane (1ml)) BAKERBOND spe™ Aromatic Sulfonic Acid (SO 3 H) disposable Extraction Columns. The columns were allowed to drain and then washed with methanol (2x1 ml) these solvents were discarded. The desired product was eluted from the column using a solution of 2M ammonia in methanol (3xlml) and concentrated to dryness in a tared 2-dram vial. The product was analyzed by LCMS (liquid chromatography mass spec). Synthesis of Compound 450: To dibenzofuran-2-yl-amine (0.91 g, 5 mmol) taken in dichloromethane (75 mL) was added ,α'-dibromo-ortho-xylene (1.85 g, 7 mmol) followed by triethylamine (3.03 g, 30 mmol). The reaction was stirred at room temperature for 24 hours. The solvents were evaporated and the residue was purified by flash silica gel chromatography to give the title compound (1.43 g). Synthesis of Compound 451: To dibenzofuran-2-yl-amine (0.91 g, 5 mmol) taken in dichloromethane (75 mL) was added phthaloyl dichloride (1.16 g, 6 mmol) followed by triethylamine (3.03 g, 30 mmol). The reaction was stirred at room temperature for 5 minutes. The reaction was quenched with sodium bicarbonate solution and the organic layer was separated. The crude product was purified by flash silica gel chromatography to give the title compound (0.51 g). Synthesis of Compound 463: To compound 58 (0.25 g, 0.87 mmol) taken in tetrahydrofuran (10 mL) was added sodium hydride (60% in mineral oil, 0.035 g, 0.87 mmol). To it methyl iodide (0.25 g, 1.74 mmol) was added. The reaction was stirred at room temperature for 24 hours. The solvents were evaporated and the residue was purified by flash silica gel chromatography to give the title compound (0.18 g). Deprotection of t-butyloxycarbonyl group: The general procedure for the removal of tert-butyoxycarbonyl (Boc) group is as follows : To the compound taken a flask was added hydrochloric acid in an appropriate solvent (dioxane, methanol, 1,2- dichloromethane and the reaction was kept under shaking for 5 to 18 hours. Removal of volatiles furnished the corresponding product. Reagents 1 are shown in Table 1. Table 1: Aldehydes/ketones (reagent 1) No. Reagent 1 (aldehydes/ketones) 1 o-tolualdehyde 2 meta-tolualdehyde 3 para-tolualdehyde 2-fluorobenzaldehyde 3-fluorobenzaldehyde 4-fluorobenzaldehyde 4-tert-butylb enzaldehyde α,α, -Trilfluoro-o-tolualdehyde α,α,α-Trilfluoro-m-tolualdehyde α, ,α-Trilfluoro-p-tolualdehyde o-anisaldehyde m-anisaldehyde p-anisaldehyde Salicylaldehyde 3 -hy droxybenzaldehyde 4-hydroxybenzaldehyde 2-chlorobenzaldehyde 3 -chlorobenzaldehyde 4-chlorobenzaldehyde 3 -benzyloxybenzaldehyde 4-benzyloxybenzaldehyde 2,3 -dimethoxybenzaldehyde 2,4-dimethoxybenzaldehyde 2, 5 -dimethoxybenzaldehyde 2, 6-dimethoxyb enzaldehyde 3 ,4-dimethoxybenzaldehyde 3 , 5 -dimethoxybenzaldehyde l,4-Benzodioxan-6-carboxaldehyde 2,4-dimethylbenzaldehyde 2, 5-dimethylbenzaldehyde 2,3 -difluorobenzaldehyde 2,4-difluorobenzaldehyde 2, 5-difluorobenzaldehyde 2, 6-difluorobenzaldehyde 3 ,4-difluorobenzaldehyde 3 , 5 -difluorob enzaldehyde ,3,4-trifluorobenzaldehyde ,3,6-trifluorobenzaldehyde -fluoro-2-methylb enzaldehyde -fluoro-p-anisaldehyde -pyridinecarboxaldehyde 3 -pyridinecarboxaldehyde -pyridinecarboxaldehyde 4-pyridinecarboxaldehyde N-oxide 6-methyl-2-pyridinecarboixaldehyde 3-furaldehyde 2-furaldehyde 5-chloro-2-thiophenecarboxaldehyde 3 -thiophenecarboxaldehy de 2-thiophenecarboxaldehyde pyrrole-2-carboxaldehyde 1 -methyl-2-pyrrolecarboxaldehy de 1 -naphthaldehyde 2-naphthaldehyde 2-quinolinecarboxaldehyde 3-quinolinecarboxaldehyde 4-quinolinecarboxaldehyde indole-3 -carboxaldehyde 2-bromobenzaldehyde 2-chlorobenzaldehyde 2-ethoxybenzaldehyde 2-cyanobenzaldehyde 5-(2-chlorophenyl)furfural 5 -(3 -chlorophenyl)furfural 5 -(4-chlorophenyl)furfural 2-thiazolecarboxaldehyde 2-imidazolecarboxaldehyde 4(5)-imidazolecaboxaldehyde 5-nitro-2-thiophenecarboxaldehyde 2-nitrobenzaldehyde 4-formyluracil 4-acetoxybenzaldehyde 4-(dimethylamino)benzaldehyde 1 -acetyl-3 -indolecarboxaldehyde 4-bromo-2-thiophenecarboxaldehyde Piperonal 3 -trifluoromethoxyb enzaldehyde 4-chloro-3 -nitro-benzaldehyde Benzaldehyde 3 -benzyloxybenzaldehyde 3 -phenoxyb enzaldehyde 2-butanone > 2-Pentanone 3 -Methyl-2-butanone Tetrahydrothiophene-3 -one Tetrahydrothiopyran-4-όne Cycloheptanone Cyclooctanone Cyclohexylmethylketone 4-Methyl-2-pentanone 3-Pentanone 3-Hexanone 4-Hydroxy-3 -methyl-2-butanon 2-Methoxyphenylacetone 4-nitrobenzaldehyde 4-(methylthio)benzaldehyde Propionaldehyde Isovaleraldehyde 3 -(methylthio)propional"dehyde 1 -phenyl-2-pentanone Acetone . Cyclopropyl methyl ketone 103 Cyclohexanone 104 n-tert-butoxycarbonyl-4-piperidone 105 3,3,5,5 -tetramethylcy clohexanone 106 1-decalone 107 4-cyclohexylcyclohexanone 108 2-norbornanone 109 4-tert-butylcyclohexanone 110 Cyclopentanone 111 2-adamantanone 112 Bicyclo[3,2, l]octan-2-one 113 1 , 1 -dioxo-tetrahydro-thiopyran-4-one Reagent 2 (amines) used in the above general procedures are shown in Table 2: Table 2: No. Reagent 2 (amines) 1 Dibenzoftιran-2-yl-methyl-amine 2 8-fluoro-dibenzofuran-2-yl-amine 3 8-chloro-dibenzofuran-2-yl-amine 4 8-amino-dibenzofuran-2-ol 5 3 -methoxy-diebenzofijran-2-yl-amine 6 9H-Fluoren-3-yl-amine 7 9H-Fluorene-2-yl-amine 8 Dibenzofuran-4-yl-amine 9 Benzo[4,5]furo[2,3-H pyridin-3-yl-amine 10 9-Ethyl-9H-carbazol-3-ylamine 11 3-Amino-carbazole-9-carboxylic acid tert-butyl ester 12 Dibenzofiιran-2-yl-methyl-amine 13 Dibenzofiιran-2-yl-dimethyl-amine 14 Dibenzothiophene-2-yl-amine 15 Dibenzothiophene-3-yl-amine 16 6-Amino-l,2,3,4-tetrahydro-carbazole-9-carboxylic acid tert-butyl ester 17 Dibenzo[l,4]dioxin-2-yl-amine 18 Phenoxanthiin-3-yl-amine 19 10-Oxa-9-thia- 1 -aza-anthracen-3 -yl-amine 20 10H-Benzo-b]pyrido[2,3-e][l,4]oxazin-3-ylamine acetic acid, tert-butyl ester 21 Anthracen-2-yl-amine 22 10, 11 l-Dihydro-5H-diebnzo[b,f]azepin-3-yl-amine 23 6,7, 8,9-Tetrahydro-5H-carbazol-3 -yl-amine 24 7-Amino-l-aza-phenoxathiin The compounds of Formula I include: 1 (l-Cyclopropyl-ethyl)-(2-methoxy-dibenzofuran-3-yl)-amine 2 Cyclopentyl-(9H-fluoren-2-yl)-amine 3 (1 -Cyclopropyl-ethyl)-(9H-fluoren-2-yl)-amine 4 N 3 -Cyclopentyl-N 2 ,N 2 -dimethyl-9H-fluorene-2,3 -diamine 5 Isopropyl-(2-methoxy-dib enzofuran-3 -yl)-amine 6 (2-Methoxy-dibenzofuran-3 -yl)-(tetrahydro-thiopyran-4-yl)-amine 7 Cycloheptyl-(2-methoxy-dibenzofuran-3 -yl)-amine 8 (l-Ethyl-propyl)-(2-methoxy-dibenzofiiran-3-yl)-amine 9 sec-Butyl-(2-methoxy-dib enzofiιran-3 -yl)-amine 10 N 2 ,N 2 -Dimethyl-N 3 -piperidin-4-yl-9H-fluorene-2,3 -diamine 1 1 N 3 -(l-Benzyl-butyl)-N 2 ,N 2 -dimethyl-9H-fluorene-2,3-diamine 12 (9H-Fluoren-2-yl)-piperidin-4-yl-amine 13 (1 -Benzyl-butyl)-(9H-fluoren-2-yl)-amine 14 sec-Butyl-(9H-fluoren-2-yl)-amine 15 (1,1 -Dioxo-hexahydro-thiopyran-4-yl)-(2-methoxy-dib enzofuran-3 -yl)-amine 16 Dibenzofuran-2-yl-(3 ,3 , 5, 5-tetramethyl-cyclohexyl)-amine 17 (Decahydro-naphthalen- 1 -yl)-dibenzofuran-2-yl-amine 18 Adamantan-2-yl-dibenzofiιran-2-yl-amine 19 Bicyclohexyl-4-yl-dibenzofuran-2-yl-amine 20 Bicyclo[2.2. l]hept-2-yl-dibenzofuran-2-yl-amine 21 (4-tert-Butyl-cyclohexyl)-dibenzofuran-2-yl-amine 22 Bicyclo[3.2. l]oct-2-yl-dibenzofuran-2-yl-amine 23 Cyclopentyl-dibenzoflιran-2-yl-amine 24 Cyclohexyl-(2-methoxy-dibenzofuran-3 -yl)-amine Cyclohexyl-(9H-fluoren-2-yl)-amine Dibenzofuran-2-yl-bis-(3 -methylsulfanyl-propyl)-amine Dibenzofuran-2-yl-bis-(3 -methyl-butyl)-amine Dibenzofiιran-2-yl-dipropyl-amine N 3 -(l,l-Dioxo-hexahydro-thiopyran-4-yl)-N 2 ,N 2 -dimethyl-9H-fluorene-2,3- diamine N 3 -Isoproρyl-N 2 ,N 2 -dimethyl-9H-fluorene-2,3 -diamine N 2 ,N 2 -Dimethyl-N 3 -(tetrahydro-thiopyran-4-yl)-9H-fluorene-2,3 -diamine N 3 -Cyclohexyl-N 2 ,N 2 -dimethyl-9H-fluorene-2,3-diamine N 3 -Cycloheptyl-N 2 ,N 2 -dimethyl-9H-fluorene-2,3 -diamine N 3 -(l -Ethyl-propyl)-N 2 ,N 2 -dimethyl-9H-fluorene-2,3 -diamine N 3 -(l-Cycloρropyl-ethyl)-N 2 ,N 2 -dimethyl-9H-fluorene-2,3-diamine N 3 -sec-Butyl-N 2 ,N 2 -dimethyl-9H-fluorene-2,3 -diamine (9H-Fluoren~2-yl)-isopropyl-amine (9H-Fluoren-2-yl)-(tetrahydro-thiopyran-4-yl)-amine Cycloheptyl-(9H-fluoren-2-yl)-amine Dibenzofuran-2-yl-(l, l-dioxo-hexahydro-thiopyran-4-yl)-amine Dibenzofuran-2-yl-piperidin-4-yl-amine Dibenzofiιran-2-yl-isopropyl-amine Cyclohexyl-dibenzofuran-2-yl-amine (l-Cyclopropyl-ethyl)-dibenzofuran-2-yl-amine Dibenzofuran-3 -yl-( 1 , 1 -dioxo-hexahydro-thiopyran-4-yl)-amine Dibenzofuran-3 -yl-piperidin-4-yl-amine Dibenzofuran-3 -yl-isopropyl-amine Dibenzofuran-3 -yl-(tetrahydro-thiopyran-4-yl)-amine Cyclohexyl-dibenzofuran-3 -yl-amine Cycloheptyl-dibenzofuran-3 -yl-amine (4-Chloro-benzyl)-dibenzofuran-2-yl-amine (4-Chloro-3-nitro-benzyl)-dibenzofuran-2-yl-amine Dibenzofuran-2-yl-(3 -trifluoromethoxy-benzyl)-amine Benzo[l,3]dioxol-5-ylmethyl-dibenzofuran-2-yl-amine Dibenzofuran-2-yl-(2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)-amine Dibenzofuran-2-yl-(3 , 5 -dimethoxy-benzyl)-amine Dibenzofuran-2-yl-(4-trifluoromethyl-benzyl)-amine Dibenzofuran-2-yl-(2-methyl-benzyl)-amine Dibenzofuran-2-yl-thiophen-3 -ylmethyl-amine Dibenzofuran-2-yl-(4-nitro-benzyl)-amine Dibenzofuran-2-yl-(4-methylsulfanyl-benzyl)-amine Dibenzofuran-2-yl-(4-methyl-b enzyl)-amine Benzyl-dibenzofuran-2-yl-amine (3 -Benzyloxy-benzyl)-dibenzofuran-2-yl-amine (1 -Benzyl-butyl)-dibenzofuran-2-yl-amine Dibenzofuran-2-yl-[2-(2-methoxy-phenyl)- 1 -methyl-ethylj-amine 3 -(Dibenzofuran-2-ylamino)-2-methyl-butan- 1 -ol Dibenzofuran-2-yl-(l-ethyl-butyl)-amine Dibenzo_furan-2-yl-(l -ethyl-propyl)-amine Dibenzofuran-2-yl-( 1 ,3 -dimethyl-butyl)-amine (l-Cyclohexyl-ethyl)-dibenzofuran-2-yl-amine Cyclooctyl-dibenzofuran-2-yl-amine Cycloheptyl-dibenzofuran-2-yl-amine Dibenzofuran-2-yl-(tetrahydro-thiopyran-4-yl)-amine Dibenzofuran-2-yl-(tetrahydro-thiophen-3 -yl)-amine Dibenzofuran-2-yl-(l,2-dimethyl-propyl)-amine Dibenzofuran-2-yl-(l-methyl-butyl)-amine sec-Butyl-dibenzofuran-2-yl-amine Benzofiιrp[3,2-b]pyridin-8-yl-(2-fluoro-benzyl)-amine Benzofuro[3,3-b]pyridin-8-yl-pyridin-4-ylmethyl-amine Benzofuro[3 ,2-b]pyridin-8-yl-(2-methyl-benzyl)-amine N-(2-Fluoro-benzyl)-N'-methyl-dibenzofuran-2,8-diamine N-Methyl-N'-quinolin-4-ylmethyl-dibenzofuran-2,8-diamine N-Methyl-N'-naphthanlen- 1 -ylmethyl-dibenzofuran-2, 8-diamine N-(4-Methanesulfonyl-benzyl)-N'-methyl-diebnzofuran-2,8-diamine N-Methyl-N' -pyridin-4-ylmethyl-dibensofuran-2, 8-diamine N-Methyl-N' -(2-methyl-benzyl)-dibenzofuran-2, 8-diamine Naphthanlen- 1 -ylmethyl-( 10H-phenothiazin-2-yl)-amine (4-Methanesulfonyl-benzyl)-(10H-phenothiazin-2-yl)-amine 90 (3 -Fluoro-2-methyl-benzyl)-(l 0-oxa-9-thia- 1 -aza-anthracen-6-yl)-amine 91 (2-Fluoro-2-methyl-benzyl)-(l 0-oxa-9-thia- 1 -aza-anthracen-6-yl)-amine 92 (10-Oxa-9-thia- 1 -aza-anthracen-6-yl)-qinolin-4-ylmethyl-amine 93 Naphthalene-l-ylmethyl-(10-oxa-9-thia-l-aza-anthracen-6-yl)-amine 94 (4-Methanesulfonyl-benzyl)-(10-oxa-9-thia-l-aza-anthracen-6-yl)-amine 95 (10-Oxa-9-thia- 1 -aza-anthracen-6-yl)-pyridin-4-ylmethyl-amine 96 (2-Methyl-benzyl)-(l 0-oxa-9-thia- 1 -aza-anthracen-6-yl)-amine 97 Anthracen-2-yl-quinolin-4-ylmethyl-amine 98 Anthracen-2-yl-(4-methanesulfonyl-benzyl)-amine 99 Anthracen-2-yl-pyridin-4-ylmethyl-amine 100 Anthracen-2-yl-(2-methyl-benzyl)-amine 101 Dibenzo[b,e][l,4]-dioxin-2-yl-(2-fluoro-benzyl)-amine 102 Dibenzo[b,e][l,4]dioxin-2-yl-(2-fluoro-benzyl)-amine 103 Dibenzo[b,e][l,4]fioxin-2-yl-quinolin-4-ylmethyl-amine 104 Dibenzo [b, e] [ 1 ,4]fioxin-2-yl-naphthalen- 1 -ylmethyl-amine 105 Dibenzo [b, e] [ 1 ,4]fioxin-2-yl-(4-methanesulfonyl-b enzyl)-amine 106 Dibenzo[b,e][l,4]fioxin-2-yl-pyridin-4-ylmethyl-amine 107 8-(3-Fluoro-2-methyl-benzylamino)-dibenzofuran-2-ol 108 8-(2-Fluoro-benzylamino)-dibenzofiιran2-ol 109 8-(4-Methanesulfonyl-benzylamino)-dibenzofuran-2-ol 1 10 8-[(Pyridin-4-ylmethyl)-amino]-dibenzofuran-2-ol 1 11 8-(2-Methyl-benzylamino)-dibenzofuran-2-ol 112 (8-Chloro-dibenzofuran-2-yl)-(2-fluoro-benzyl)-amine 1 13 8-Chloro-dibenzofuran-2-yl)-naphthalen- 1 -ylmethyl-amine 114 8-Chloro-dibenzofiιran-2-yl)-(4-methanesulfonyl-benzyl)-amine 115 (4-Methanesulfonyl-benzyl)-(6,7,8,9-tetrahydro-5H-carbazol-3-yl)-amine 116 Pyridin-4-ylmethyl-(6,7,8,9-tetrahydro-5H-carbazol-3-yl)-amine 117 Benzofuro[3,2-b]pyridin-8-yl-(3-fluoro-2-methyl-benzyl)-amine 118 Dibenzofuran-2-yl-quinolin-4-ylmethyl-amine 119 Dibenzofuran-2-yl-quinolin-2-ylmethyl-amine 120 (4-Dimethylamino-benzyl)-(8-fluoro-dibenzofiιran-2-yl)-amine 121 Dibenzofuran-2-yl-(4-dimethylamino-benzyl)-amine 122 Diebnzofuran-2-yl-(5-nitro-thiophen-2-ylmethyl)-amine 123 Dibenzofiιran-2-yl-thiazol-2-ylmethyl-amine 124 Benzyl-(8-fluoro-dibenzofuran-2-yl)-amine 125 N-(-3-Methoxybenzyl)-N'-methyl-dibenzofuran-2,8-diamine 126 N-(3,5-Dimethoxy-benzyl)-N'-methyl-dibenzofuran-2, 8-diamine 127 N- 4-tert-Butyl-benzyl)-N'-methyl-dibenzofiιran-2,8-diamine 128 N-Benzyl-N' -methyl-dibenzofuran-2, 8-diamine 129 2-[(8-Methylamino-dibenzofuran-2-ylamino)-methyl]-benzonitrile 130 (4-Methoxy-benzyl)-phenoxathiin-3 -yl-amine 131 (8-Chloro-dibenzofuran-2-yl)-(3 -methoxy-benzyl)-amine 132 (3 -Methoxy-b enzyl)-phenoxathiin-3 -yl-amine 133 (3,5 -Dimethoxy-b enzyl)-phenoxathiin-3 -yl-amine 134 (3 -Fluoro-4-methoxy-benzyl)-phenoxathiin-3 -yl-amine 135 (4-tert-Butyl-benzyl)-phenoxathiin-3 -yl-amine 136 Benzyl-phenoxathiin-3 -yl-amine 137 (2-Ethoxy-benzyl)-phenoxathiin-3-yl-amine 138 (8-Chloro-dibenzofuran-2-yl)-(3,5-dimethoxy-benzyl)-amine 139 (8-Chloro-dibenzofuran-2-yl)-(3-fluoro-4-methoxy-benzyl)-amine 140 Benzyl-(8-chloro-dibenzofuran-2-yl)-amine 141 (9H-Fluoren-2-yl)-(4-methoxy-benzyl)-amine 142 (8-Chloro-dibenzofuran-2-yl)-thiazol-2-ylmethyl-amine 143 (9H-Fluoren-2-yl)-(3 -methoxy-benzyl)-amine 144 (3,5-Dimethoxy-benzyl)-(9H-fluoren-2-yl)-amine 145 (9H-Fluoren-2-yl)-(3-fluoro-4-methoxy-benzyl)-amine 146 (4-tert-Butyl-benzyl)-(9H-fluoren-2-yl)-amine 147 Benzyl-(9H-fluoren-2-yl)-amine 148 (9H-Fluoren-2-yl)-thiazol-2-ylmethyl-amine 149 (2-Ethoxy-benzyl)-(9H-fluoren2-yl-amine 150 Dibenzofuran-4-yl-(4-methoxy-benzyl)-amine 151 2-[(8-Chloro-dibenzofuran-2-ylamino)-methyl]-benzonitrile 152 Dibenzofiιran-4-yl-(3-methoxy-benzyl)-amine 153 Dibenzofuran-4-yl-(3 , 5-dimethoxy-benzyl)-amine 154 Dibenzofuran-4-yl-(3-fluoro-4-methoxy-benzyl)-amine 155 (4-tert-Butyl-benzyl)-dibenzofiιran-4-yl-amine 156 Dibenzofuran-4-yl-(2-ethoxy-benzyl)-amine 157 N-(4-Methoxy-benzyl)-N' -methyl-dibenzofuran-2, 8-diamine 158 (8-Chloro-dibenzofuran-2-yl)(4-methoxy-benzyl)-amine 159 (8-Chloro-dibenzofiiran-2-yl)-(2-ethoxy-benzyl)-amine 160 Dibenzof_uran-4-yl-(2,4-dimethyl-benzyl)-amine 161 N-Methyl-N'-thiophen-3-ylmethyl-dibenzofuran-2,8-diamine 162 N-Methyl-N'-pyridin-2-ylmethyl-dibenzofuran-2, 8-diamine 163 (2-Bromo-benzyl)-phenoxathiin-3 -yl-amine 164 Phenoxathiin-3 -yl-quinolin-4-ylmethyl-amine 165 Phenoxathiin-3 -yl-thiophen-3 -ylmethyl-amine 166 (3 -Methyl-pyridin-2-ylmethyl)-phenoxathiin-3 -yl-amine 167 Phenoxathiin-3 -yl-pyridin-3 -ylmethyl-amine 168 Phenoxathiin-3 -yl-pyridin-2-ylmethyl-amine 169 (8-Chloro-dibenzofuran-2-yl)-thiophen-3 -ylmethyl-amine 170 (2-Bromo-benzyl)-(9-ethyl-9H-carbazol-3-yl)-amine 171 (8-Chloro-dibenzofuran-2-yl)-(3 -methyl-pyridin-2-ylmethyl)-amine 172 (9-Ethyl-9H-carbazol-3 -yl)-thiophen-3 -ylmethyl-amine 173 (5-Chloro-thioρhen-2-ylmethyl)-(9-ethyl-9H-carbazol-3-yl)-amine 174 (9-Ethyl-9H-carbazol-3 -yl)-pyridin-3 -ylmethyl-amine 175 (2-Bromo-benzyl)-(9H-fluoren-2-yl)-amine 176 (8-Chloro-dibenzofuran-2-yl)-pyridin-4-ylmethyl-amine 177 (9H-Fluoren-2-yl)-quinolin-2-ylmethyl-amine 178 (9H-Fluoren-2-yl)-thiophen-3 -ylmethyl-amine 179 (9H-Fluoren-2-yl)-(3-methyl-pyridin-2-ylmethyl)-amine 180 (9H-Fluoren-2-yl)-pyridin-4-ylmethyl-amine 181 (9H-Fluoren-2-yl)-pyridin-3 -ylmethyl-amine 182 (9H-Fluoren-2-yl)-pyridin-2-ylmethyl-amine 183 (8 -Chloro-dibenzofuran-2-yl)-pyridin-3 -ylmethyl-amine 184 Dibenzofuran-4-yl-quinolin-4-ylmethyl-amine 185 Dibenzofuran-4-yl-quinolin-2-ylmethyl-amine 186 Dibenzofuran-4-yl-thiophen-3 -ylmethyl-amine 187 Dibenzofuran-4-yl-(3-methyl-pyridin-2-ylmethyl)-amine 188 Dibenzofuran-4-yl-pyridin-4-ylmethyl-amine 189 Dibenzofuran-4-yl-ρyridin-3 -ylmethyl-amine 190 Dibenzofuran-4-yl-ρyridin-2-ylmethyl-amine 191 (2-Bromo-benzyl)-(8-chloro-dibenzofuran-2-yl)-amine 192 (8-Chloro-dibenzofuran-2-yl)-pyridin-2-ylmethyl-amine 193 N-Methyl-N'-(2,3,6-trifluoro-benzyl)-dibenzofuran-2,8-diamine 194 N-Methyl-N'-(2,3 ,4-trifluoro-benzyl)-dibenzofuran-2, 8-diamine 195 N-(2, 6-Difluoro-benzyl)-N'-methyl-dibenzofuran-2, 8-diamine 196 N-(2, 5-Difluoro-benzyl)-N'-methyl-dibenzofuran-2, 8-diamine 197 N-(2,4-Difluoro-benzyl)-N'-methyl-dibenzofuran-2,8-diamine 198 N-(2,3-Difluoro-benzyl)-N'-methyl-dibenzofuran-2,8-diamine 199 N-(2,5-Dimethyl-benzyl)-N'-methyl-dibenzofuran-2,8-diamine 200 N-(2,4-Dimethyl-benzyl)-N'-methyl-dibenzofuran-2,8-diamine 201 N-(2,3-Dihydro-benzo[l,4]dioxin-6-ylmethyl)-N'-methyl-dibenzofuran-2,8- diamine 202 (3 -Fluoro-2-methyl-benzyl)-phenoxathiin-3 -yl-amine 203 (8-Chloro-dibenzofuran-2-yl)-(2,3,6-trifluoro-benzyl)-amine 204 Phenoxathiin-3-yl-(2,3,6-trifluoro-benzyl)-amine 205 Phenoxathiin-3 -yl-(2,3 ,4-trifluoro-benzyl)-amine 206 (2, 6-Difluoro-benzyl)-phenoxathiin-3 -yl-amine 207 (2, 5-Difluoro-benzyl)-phenoxathiin-3 -yl-amine 208 (2, 4-Difluoro-benzyl)-phenoxathiin~3 -yl-amine 209 (2,3 -Difluoro-benzyl)-phenoxathiin-3 -yl-amine 210 (2,4-Dimethyl-benzyl)-phenoxathiin-3 -yl-amine 211 (2,3 -Dihy dro-benzo [1,4] dioxin-6-ylmethyl)-phenoxathiin-3 -yl-amine 212 Benzo[b]thiophen-5-yl-(3-fluoro-2-methyl-benzyl)-amine 213 (8-Chloro-dibenzofuran-2-yl)-(2,3,4-trifluoro-benzyl)-amine 214 (8-Chloro-dibenzofuran-2-yl)-(2,6-difluoro-benzyl)-amine 215 (8-Chloro-dibenzofuran-2-yl)-(2,5-difluoro-benzyl)-amine 216 (8-Chloro-dibenzofuran-2-yl)-(2,4-difluoro-benzyl)-amine 217 (9-Ethyl-9H-carbazol-3 -yl)-(3 -fluoro-2-methyl-benzyl)-amine 218 (8-Chloro-dibenzofuran-2-yl)-(2,3 -difluoro-benzyl)-amine 219 (9-Ethyl-9H-carbazol-3-yl)-(2,3,6-trifluoro-benzyl)-amine 220 (9-Ethyl-9H-carbazol-3 -yl)-(2,3 ,4-trifluoro-benzyl)-amine 221 (2,6-Difluoro-benzyl)-(9-ethyl-9H-carbazol-3-yl)-amine 222 (2,5-Difluoro-benzyl)-(9-ethyl-9H-carbazol-3-yl)-amine 223 (2,4-Difluoro-benzyl)-(9-ethyl-9H-carbazol-3 -yl)-amine 224 (2,3 -Difluoro-benzyl)-(9-ethyl-9H-carbazol-3 -yl)-amine 225 (2,5-Dimethyl-benzyl)-(9-ethyl-9H-carbazol-3-yl)-amine 226 (2,4-Dimethyl-benzyl)-(9-ethyl-9H-carbazol-3 -yl)-amine 227 (2,3-Dihydro-benzo[l,4]dioxin-6-ylmethyl)-(9-ethyl-9H-carbazol-3-yl)-amine 228 (9H-Fluoren-2-yl)-(3 -fluoro-2-methyl-benzyl)-amine 229 (8-Chloro-dibenzofuran-2-yl)-(2, 5-dimethyl-benzyl)-amine 230 (9H-Fluoren-2-yl)-(2,3,6-trifluoro-benzyl)-amine 231 (9H-Fluoren-2-yl)-(2,3,4-trifluoro-benzyl)-amine 232 (2,5-Difluoro-benzyl)-(9H-fluoren-2-yl)-amine 233 (2,4-Difluoro-benzyl)-(9H-fluoren-2-yl)-amine 234 (2,3 -Difluoro-benzyl)-(9H-fluoren-2-yl)-amine 235 (2,5-Dimethyl-benzyl)-(9H-fluoren-2-yl)-amine 236 (2,4-Dimethyl-benzyl)-(9H-fluoren-2-yl)-amine 237 (2,3-Dihydro-benzo[l,4]dioxin-6-ylmethyl)-(9H-fluoren-2-yl)-amine 238 (8-Chloro-dibenzofuran-2-yl)-(2,4-dimethyl-benzyl)-amine 239 Dibenzofuran-4-yl-(2,5-dimethyl-benzyl)-amine 240 Dibenzofuran-4-yl-(3 -fluoro-2-methyl-benzyl)-amine 241 N-(3 -Fluoro-2-methyl-benzyl)-N'-methyl-dibenzofiιran-2, 8-diamine 242 (8-Chloro-dibenzofuran-2-yl)-(3 -fluoro-2-methyl-benzyl)-amine 243 (8-Chloro-dibenzofuran-2-yl)-(2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)-amine 244 (2,5-Dimethoxy-benzyl)-phenoxathiin-3-yl-amine 245 (2,3 -Dimethoxy-b enzyl)-phenoxathiin-3 -yl-amine 246 (2-Chloro-benzyl)-phenoxathiin-3 -yl-amine 247 (2-Methoxy-benzyl)-phenoxathiin-3 -yl-amine 248 (2-Methyl-benzyl)-phenoxathiin-3 -yl-amine 249 Anthracen-2-yl-(2-chloro-benzyl)-amine 250 Anthracen-2-yl-(2-fluoro-benzyl)-amine 251 Dibenzo [1,4] dioxin-2-yl-(2,3 -dimethoxy-benzyl)-amine 252 (2-Chloro-benzyl)-dibenzo[l,4]dioxin-2-yl-amine 253 2-(Dibenzo[l,4]dioxin-2-ylaminomethyl)-phenol 254 Dibenzo[l,4]dioxin-2-yl-(2-methoxy-benzyl)-amine 255 2-[(9-Ethyl-9H-carbazol-3-ylamino)-methyl]-phenol 256 (9-Ethyl-9H-carbazol-3 -yl)-(2-fluoro-benzyl)-amine 257 (9-Ethyl-9H-carbazol-3 -yl)-(2-methyl-benzyl)-amine 258 (2-Chloro-benzyl)-(9H-fluoren-2-yl)-amine 259 2-[(9H-Fluoren-2-ylamino)-methyl]-phenol 260 (9H-Fluoren-2-yl)-(2-methoxy-benzyl)-amine 261 (9H-Fluoren-2-yl)-(2-trifluoromethyl-benzyl)-amine 262 (9H-Fluoren-2-yl)-(2-fluoro-benzyl)-amine 263 Dibenzofuran-4-yl-(2,5-'dimethoxy-benzyl)-amine 264 Dibenzofuran-4-yl-(2,3 -dimethoxy-benzyl)-amine 265 2-(Dibenzofuran-4-ylaminomethyl)-phenol 266 Dibenzofuran-4-yl-(2-methoxy-benzyl)-amine 267 (2,5-Dimethoxy-benzyl)-(3-methoxy-dibenzofuran-2-yl)-amine 268 (2,3 -Dimethoxy-benzyl)-(3 -methoxy-dibenzofuran-2-yl)-amine 269 (2-Methoxy-benzyl)-(3 -methoxy-dibenzofiιran-2-yl)-amine 270 Dibenzofuran-2-yl-(2, 5-dimethoxy-benzyl)-amine 271 Dibenzofuran-2-yl-(4-methoxy-benzyl)-amine 272 (2-Bromo-benzyl)-dibenzofuran-2-yl-amine 273 (8 -Fluoro-dibenzofuran-2-yl)-(3H-imidazol-4-ylmethyl)-amine 274 2-[(8-Fluoro-dibenzofuran-2-ylamino)-methyl]-benzonitrile 275 (2-Ethoxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 276 (8-Fluoro-dibenzofuran- : 2-yl)-(4-methylsulfanyl-benzyl)-amine 277 (2-Bromo-benzyl)-(8-fluoro-dibenzofi_ιran-2-yl)-amine 278 (8-Fluoro-dibenzofuran-2-yl)-quinolin-4-ylmethyl-amine 279 (8-Fluoro-dibenzofuran-2-yl)-quinolin-2-ylmethyl-amine 280 Dibenzofuran-2-yl-naphthalen- 1 -ylmethyl-amine 281 (8-Fluoro-dibenzofuran-2-yl)-naphthalen-2-ylmethy 1-amine 282 (8-Fluoro-dibenzofuran-2-yl)-naphthalen- 1 -ylmethyl-amine 283 Dibenzofuran-2-yl-(2-nitro-benzyl)-amine 284 Dibenzoj[_uran-2-yl-(3H-imidazol-4-ylmethyl)-amine 285 2-(Dibenzofuran-2-ylaminomethyl)-benzonitrile 286 Dibenzofuran-2-yl-(2-ethoxy-benzyl)-amine 287 Dibenzofuran-2-yl-(3 -trifluoromethyl-benzyl)-amine 288 (4-tert-Butyl-benzyl)-dibenzofuran-2-yl-amine 289 Dibenzofuran-2-yl-(3 -fluoro-benzyl)-amine 290 (2,5-Dimethoxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 291 (2,3 -Dimethoxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 292 (4-Benzyloxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 293 (3 -Benzyloxy-benzyl)-(8-fluoro-dibenzofiιran-2-yl)-amine 294 (4-Chloro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 295 (3 -Chloro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 296 (2-Chloro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 297 4-[(8-Fluoro-dibenzofuran-2-ylamino)-methyl]-phenol 298 3-[(8-Fluoro-dibenzofuran-2-ylamino)-methyl]-phenol 299 Dibenzofuran-2-yl-(2-fluoro-benzyl)-amine 300 (8-Fluoro-dibenzofuran-2-yl)-(4-methoxy-benzyl)-amine 301 (8-Fluoro-dibenzofuran-2-yl)-(3 -methoxy-benzyl)-amine 302 (8-Fluoro-dibenzofuran-2-yl)-(2-methoxy-benzyl)-amine 303 (8-Fluoro-dibenzofuran-2-yl)-(4-trifluoromethyl-benzyl)-amine 304 (8-Fluoro-dibenzofuran-2-yl)-(3 -trifluoromethyl-benzyl)-amine 305 (4-tert-Butyl-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 306 (4-Fluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 307 (3 -Fluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 308 (2-Fluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 309 (8-Fluoro-dibenzofuran-2-yl)-(4-methyl-benzyl)-amine 310 (8-Fluoro-dibenzofuran-2-yl)-(3 -methyl-benzyl)-amine 311 Dibenzofiιran-2-yl-(2,6-dimethoxy-benzyl)-amine 312 Dibenzofuran-2-yl-(2,4-dimethoxy-benzyl)-amine 313 Dibenzofuran-2-yl-(2,3 -dimethoxy-benzyl)-amine 314 (4-Benzyloxy-benzyl)-dibenzofuran-2-yl-amine 315 Dibenzofiιran-2-yl-(3 -methyl-b enzyl)-amine 316 (3 -Chloro-benzyl)-dibenzofuran-2-yl-amine 317 3-(Dibenzofuran-2-ylaminomethyl)-phenol 318 (2-Chloro-benzyl)-dibenzofixran-2-yl-amine 319 Dibenzo&ran-2-yl-(3 -methoxy-benzyl)-amine 320 Dibenzofuran-2-yl-(2-methoxy-benzyl)-amine 321 (9H-Fluoren-2-yl)-(2-methyl-benzyl)-amine 322 Dibenzofuran-4-yl-(2-methyl-benzyl)-amine 323 (8-Chloro-dibenzofuran-2-yl)-(2-methyl-benzyl)-amine 324 (2-Methyl-benzyl)-(10H-phenothiazin-2-yl)-amine 325 Dibenzo[b,e][l,4]dioxin-2-yl-(2-methyl-benzyl)-amine 326 Dibenzofuran-2-yl-(2, 6-difluoro-benzyl)-amine 327 Dibenzofuran-2-yl-(2,5-difluoro-benzyl)-amine 328 Dibenzofuran-2-yl-(2,4-difluoro-benzyl)-amine 329 Dibenzofuran-2-yl-(2,3 -difluoro-benzyl)-amine 330 (8-Fluoro-dibenzofuran-2-yl)-thiophen-2-ylmethyl-amine 331 Dibenzofuran-2-yl-(2,5-dimethyl-benzyl)-amine 332 (8-Fluoro-dibenzofuran-2-yl)-thiophen-3 -ylmethyl-amine 333 (8-Fluoro-dibenzofuran-2-yl)-furan-2-ylmethyl-amine 334 (8-Fluoro-dibenzofuran-2-yl)-furan-3 -ylmethyl-amine 335 (8-Fluoro-dibenzofuran-2-yl)-(6-methyl-pyridin-2-ylmethyl)-amine 336 (8-Fluoro-dibenzofuran-2-yl)-(4-methanesulfonyl-benzyl)-amine 337 (8-Fluoro-dibenzofuran-2-yl)-pyridin-4-ylmethyl-amine 338 (8-Fluoro-dibenzofuran-2-yl)-pyridin-3 -ylmethyl-amine 339 (8-Fluoro-dibenzofuran-2-yl)-pyridin-2-ylmethyl-amine 340 (8-Fluoro-dibenzofuran-2-yl)-(3 -fluoro-4-methoxy-benzyl)-amine 341 Dibenzofuran-2-yl-(2,4-dimethyl-benzyl)-amine 342 (8-Fluoro-dibenzofuran-2-yl)-(3 -fluoro-2-methyl-benzyl)-amine 343 (8-Fluoro-dibenzofuran-2-yl)-(2,3,6-trifluoro-benzyl)-amine 344 (8-Fluoro-dibenzofuran-2-yl)-(2,3 ,4-trifluoro-benzyl)-amine 345 (3 , 5-Difluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 346 (3 ,4-Difluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 347 (3 , 5-difluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 348 (2,6-Difluoro-benzyl (2,.5-Difluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 349 (2,4-Difluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 350 (2,3 -Difluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 351 (2,5-Dimethyl-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 352 (2,4-Dimethyl-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 353 (2,3-Dihydro-l,4-benzodioxin-6-ylmethyl)-(8-fluoro-dibenzofuran-2-yl)-amine 354 (3,5-Dimethoxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 355 Dibenzofuran-2-yl-furan-2-ylmethyl-amine 356 Dibenzofuran-2-yl-furan-3 -ylmethyl-amine 357 Dibenzofuran-2-yl-(6-methyl-pyridin-2-ylmethyl)-amine 358 Dibenzofuran-2-yl-(4-methanesulfonyl-benzyl)-amine 359 Dibenzofuran-2-yl-pyridin-4-ylmethyl-amine 360 Dibenzofiιran-2-yl-pyridin-3 -ylmethyl-amine 361 Dibenzofuran-2-yl-pyridin-2-ylmethyl-amine 362 Dibenzofiιran-2-yl-(3 -fluoro-4-methoxy-benzyl)-amine 363 Dibenzofiιran-2-yl-(3 -fluoro-2-methyl-benzyl)-amine 364 Dibenzo&ran-2-yl-(2,3,6-trifluoro-benzyl)-amine 365 Dibenzofuran-2-yl-(2,3 ,4-trifluoro-benzyl)-amine 366 Dibenzofuran-2-yl-(3,5-difluoro-benzyl)-amine 367 Dibenzofuran-2-yl-(3 ,4-difluoro-benzyl)-amine 368 Dibenzofuran-2-yl-(3 ,4-dimethoxy-benzyl)-amine 369 Dibenzofiιran-2-yl-methyl-(2-methyl-benzyl)-amine 370 Dibenzothiohen-2-yl-(2,4-dimethyl-benzyl)-amine 371 (4-tert-Butyl-benzyl)-dibenzothiohen-2-yl-amine 372 (2-Chloro-benzyl)-dibenzothiohen-2-yl-amine 373 Dibenzothiohen-2-yl-(2,6-difluoro-benzyl)-amine 374 Dibenzothiohen-2-yl-(2,3,6-trifluoro-benzyl)-amine 375 Dibenzothiohen-2-yl-(2-fluoro-benzyl)-amine 376 B enzyl-dib enzothiohen-2-yl-amine 377 Dibenzothiohen-2-yl-(4-methoxy-benzyl)-amine 378 Dibenzothiohen-2-yl-(2,3 -dimethoxy-benzyl)-amine 379 Dibenzothiohen-2-yl-(2,5-difluoro-benzyl)-amine 380 Dibenzothiohen-2-yl-(3 -methoxy-benzyl)-amine 381 Dibenzothiohen-2-yl-(2,3 ,4-trifluoro-benzyl)-amine 382 (-2-Bromo-benzyl)-dibenzothiohen-2-yl-amine 383 Dibenzothiohen-2-yl-(2,3 -dihydro- 1 ,4-benzodioxin-6-ylmethyl)-amine 384 Dibenzothiohen-2-yl-(3 -fluoro-4-methoxy-benzyl)-amine 385 Dibenzothiohen-2-yl-(2,5-dimethyl-benzyl)-amine 386 Dibenzothiohen-2-yl-thiophen-3 -ylmethyl-amine 387 Dibenzothiohen-2-yl-naphthalene-l-ylmethyl-amine 388 Dibenzothiohen-2-yl-(2-trifluoromethyl-benzyl)-amine 389 Dibenzothiohen-2-yl-naphthalen-2-ylmethyl-amine 390 Dibenzothiohen-2-yl-(2-ethoxy-benzyl)-amine 391 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(3-fluoro-2-methyl-benzyl)-amine 392 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2-methyl-benzyl)-amine 393 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2,4-dimethyl-benzyl)-amine 394 (4-tert-Butyl-benzyl)-( 10, 11 -dihydro-5H-dibenz[b,f| azepin-2-yl)-amine 395 (2-Chloro-benzyl)-(10, 1 l-dihydro-5H-dibenz[b,f]azepin-2-yl)-amine 396 (2,6-Difluoro-benzyl)-(10, 1 l-dihydro-5H-dibenz[b,f]azepin-2-yl)-amine 397 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2,3,6-trifluoro-benzyl)-amine 398 (10, 1 l-Dihydro-5H-dibenz[b,fjazepin-2-yl)-(2-fluoro-benzyl)-amine 399 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(3,5-dimethoxy-benzyl)-amine 400 Benzyl-(10,1 l-dihydro-5H-dibenz[b,f]azepin-2-yl)-amine 401 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(4-methoxy-benzyl)-amine 402 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2,3-dimethoxy-benzyl)-amine 403 (2, 5-difluoro-benzyl)-(l 0, 11 -dihydro-5H-dibenz[b,f] azepin-2-yl)-amine 404 (10, 1 l-Dihydro-5H-dibenz[b,fjazepin-2-yl)-(3-methoxy-benzyl)-amine 405 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2,3,4-trifluoro-benzyl)-amine 406 (2-Bromo-benzyl)-(10, 1 l-dihydro-5H-dibenz[b,f]azepin-2-yl)-amine 407 (2,3-Dihydro-l,4-benzodioxin-6-ylmethyl)-(10, 1 l-dihydro-5H- dibenz[b,f]azepin-2-yl)-amine 408 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(3-fluoro-4-methoxy-benzyl)-amine 409 (10, 1 l-Dihydro-5H-dibenz[b,f|azepin-2-yl)-(2,5-dimethyl-benzyl)-amine 410 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-thiophen-3 -ylmethyl-amine 411 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-naphthalen-l-ylmethyl-amine 412 (10,1 l-Dihydro-5H-dibenz[b,fjazepin-2-yl)-(2-trifluoromethyl-benzyl)-amine 413 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-naphthalen-2-ylmethyl-amine 414 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2-ethoxy-benzyl)-amine 415 (3-Fluoro-2-methyl-benzyl)-(10H-phenothiazin-2-yl)-amine 416 (2,4-Dimethyl-benzyl)-(10H-phenothiazin-2-yl)-amine 417 (4-tert-Butyl-benzyl)-(10H-phenothiazin-2-yl)-amine 418 (2-Chloro-benzyl)-(10H-phenothiazin-2-yl)-amine 419 (2,6-Difluoro-benzyl)-(10H-phenothiazin-2-yl)-amine 420 (10H-Phenothiazin-2-yl)-(2,3 ,6-trifluorobenzyl)-amine 421 (2-Fluoro-benzyl)-( 10H-phenothiazin-2-yl)-amine 422 (3,5 -Dimethoxy-b enzyl)-( 10H-phenothiazin-2-yl)-amine 423 Benzyl-(10H-phenothiazin-2-yl)-amine 424 (4-Methoxy-benzyl)-(10H-phenothiazin-2-yl)-amine 425 (2, 5 -Difluoro-benzyl)-( 10H-phenothiazin-2-yl)-amine 426 (10H-Phenothiazin-2-yl)-(2,3,4-trifluoro-benzyl)-amine 427 (2,3-Dihydro-l,4-benzodioxin-6-ylmethyl)-(10H-phenothiazin-2-yl)-amine 428 (3 -Fluoro-4-methoxy-benzyl)-( 10H-phenothiazin-2-yl)-amine 429 (2, 5-Dimethyl-benzyl)-( 10H-phenothiazin-2-yl)-amine 430 (10H-Phenothiazin-2-yl)-thiophen-3 -ylmethyl-amine 431 (10H-Phenothiazin-2-yl)-(2-trifluoromethyl-benzyl)-amine 432 (9H-Carbazol-3 -yl)-(3 -fluoro-2-methyl-benzyl)-amine 433 (9H-Carbazol-3 -yl)-(2-methyl-benzyl)-amine 434 (9H-Carbazol-3 -yl)-(2,4-dimethyl-benzyl)-amine 435 (4-tert-Butyl-benzyl)-(9H-carbazol-3-yl)-amine 436 (9H-Carbazol-3 -yl)-(2-chloro-benzyl)-amine 437 (9H-Carbazol-3 -yl)-(2, 6-difluoro-benzyl)-amine 438 (9H-Carbazol-3-yl)-(2,3,6-trifluoro-benzyl)-amine 439 (9H-Carbazol-3-yl)-(3,5-dimethoxy-benzyl)-amine 440 (9H-Carbazol-3 -yl)-(2,3 -dimethoxy-benzyl)-amine 441 (9H-Carbazol-3-yl)-(2,5-difluoro-benzyl)-amine 442 (9H-Carbazol-3 -yl)-(2,3 ,4-trifluoro-benzyl)-amine 443 (9H-Carbazol-3 -yl)-(2,3-dihydro- 1 ,4-benzodioxin-6-ylmethyl)-amine 444 (9H-Carbazol-3-yl)-(2,5-dimethyl-benzyl)-amine 445 (9H-Carbazol-3 -yl)-naphthalen- 1 -ylmethyl-amine 446 (9H-Carbazol-3 -yl)-naphthalen-2-ylmethyl-amine 447 Dibenzofuran-2-yl-bis-(2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)-amine 448 Dibenzofuran-2-yl-bis-thiophen-3 -ylmethyl-amine 449 Dibenzofuran-2-yl-(4-phenoxy-benzyl)-amine 450 2-Dibenzofuran-2-yl-2,3 -dihydro- IH-isoindole 451 2-Dibenzofiιran-2-yl~ lH-isoindole- 1 ,3 -dione 452 Dibenzofuran-2-yl-(4-trifluoromethoxy-benzyl)-amine 453 Dibenzofuran-2-yl-(2-methoxy-benzyl)-amine 454 Dibenzofiιran-2-yl-(3 -phenoxy-benzyl)-amine 455 Dibenzofuran-2-yl-methyl(2-methyl-benzyl)-amine 456 Dibenzofuran-2-yl-( 1 -phenyl-butyl)-amine 457 Dibenzofiιran-2-yl-phenethyl-amine 458 Dibenzofiιran-2-yl-(l-phenyl-ethyl)-amine EXAMPLES * Analysis was done by LCMS. Number shown is M+l. In all cases mass shown agrees with the expected mass for the compound shown. The following compounds were prepared according to the general procedure 1 : Antiviral activity assays: Screening assays: Anti-herpes simplex virus- 1 (HSV) activity is determined in a yield reduction assay utilizing a recombinant HSV (HSV US3 : : pgC-lacZ) which expresses E. coli β-galactosidase (β-gal) under the control of an HSV late gene promoter (Fink, D.J.; Sternberg, L.R.; Weber, P.C.; Mata, M.; Goins, W.F.; Glorioso, J.C. Human Gene Therapy 3:11-19, 1992). Vero (African Green Monkey kidney) cells are infected at a multiplicity of infection of 0.01 with the virus, and serial dilutions of the compound in dimethyl sulfoxide (DMSO) are added. The final concentration of DMSO in all wells is 1%. DMSO is added to control wells. The infection is allowed to proceed for 2 days at which time the β-gal activity in cell lysates is measured. Activity in wells containing compound is compared to control wells and percent inhibition determined. The EC 50 is defined as the concentration of drug that produces a 50% reduction in β-gal production relative to control wells. Anti-human cytomegalovirus (HCMV) activity is determined in a yield reduction assay utilizing a recombinant HCMV (RC256) that produces β-gal (Spaete, R.R.; Mocarski, E.S. Proceedings of the National Academy of Sciences USA 84:7213-7217, 1987). Primary human diploid fibroblasts (HFF cells) are infected at an moi of 0.01 withRC256, and serial dilutions of the compound inDMSO are added. The final concentration of DMSO in all wells is 1%. The infection is allowed to proceed for 7 days at which time the β-gal activity in cell lysates is measured. Activity in wells containing compound is compared to control wells and percent inhibition determined. The EC 50 is defined as the concentration of compound that produces a 50% reduction in β-gal production relative to control wells. TC 50 is defined as concentration of compound that produces cytotoxicity in 50% of uninfected cells. Secondary yield reduction assays: To determine the activity of compounds against HSV, Vero cells are plated in 6 well dishes at a density of 5 x 10 5 cells/well. Cells are infected at a multiplicity of infection of 0.01 with HSV (strain Synl7+). 30μL of one of six threefold serial dilutions of test compound inDMSO is added to each well at the time of infection. The plates are returned to a 37°C incubator and the infection allowed to proceed for 2 days. Aliquots of the supernatant are harvested, and the virus titer determined. Vero cells in 24 well plates are infected with threefold serial dilutions of supernatant. The virus is allowed to adsorb to the monolayer for 1.5 hours, after which it is aspirated and replaced with growth medium containing 0.5% methylcellulose. Plaques are allowed to develop for 5 days, at which time the medium aspirated and the monolayer stained with crystal violet. The plaques are enumerated under low power magnification. Percent inhibition is determined by comparison with the titer from cells infected in the presence of DMSO alone. To determine the activity of compounds against CMV, HFF cells, plated in 24 well plates at 1 x 10 5 cells/well, are infected with CMV (strain AD 169) at an moi of 0.01. 10 μL of one of six threefold dilutions of test compound in DMSO is added to each well at the time of infection. The plates are returned to a 37°C incubator and the infection allowed to proceed for 7 days. Aliquots of the supernatant of infected cells are harvested and the virus titer determined. HFF cells in 24 well plates are infected with threefold serial dilutions of supernatant. The virus is allowed to adsorb to the cells for 2 hours, at which time the inoculum is aspirated and replaced with growth medium containing 0.5% methylcellulose. The plaques are allowed to develop for 7- 10 days, at which time the medium is aspirated and the monolayer stained with crystal violet. The plaques are enumerated under low power magnification. Percent inhibition is determined by comparison with the titer from cells infected in the presence of DMSO alone. Cellular toxicity assays: Cellular toxicity is measured in HFF cells. Cells are plated in 96 well plates at IxlO 4 cells/ well. Serial dilutions of compounds are added to the wells in DMSO, with the final concentration of DMSO in all wells at 1%, in a total volume of 200μL. The plates are maintained in a 37°C incubator for 7 days. 50μL of a solution of XTT (sodium~3'[l-(phenyl-amino-carbonyl)-3,-tetrazolium]-bis(bis(4- methoxy-6-nitro)-benzene sulfonic acid hydrate) (3 x 10 "4 mg/ml) is added to each well, and the plates returned to the incubator for 4 hours, after which the A 4 50 (absorbance at wavelength of 450 nm) for each well is measured in a plate reader. (Roehm, N.W., et al J. Immunol. Meth. 142:257-265, 1991). Toxicity is determined by comparison of the OD (optical density) ofa well containing compound to the OD of wells contaimng DMSO only. The effect of test compounds on cellular DNA synthesis is measured in a 14 C- thymidine incorporation assay, utilizing scintillation proximity assay technology. Cells are plated at 2 x 10 4 cells/well in Amersham Cytostar 96 well scintillating microplates. The following day, serial dilutions of test compounds in DMSO are added to the wells, along with 0. lμCi/well of [methyl- 14 C]-thymidine (specific activity 50-62mCi/mmol). The plates are counted immediately in a μBeta scintillation counter (Wallac), to determine background, then placed in a 37°C incubator for 7 days. The plates are removed from the incubator at intervals and the thymidine incorporation into the cellular DNA determined by scintillation counting. Percent inhibition is determined by comparing 14 C incorporation in wells containing test compound to incorporation in wells containing DMSO only. Table 3 contains the results of the antiviral efficacy (HSV: EC 50 , TC50 and Tl) screening results, where Tl is the therapeutic index (TC50 EC.50). TABLE 3 Antiviral Efficacy in a Yield Reduction Assay (HSV-1) Antiviral Efficacy (Vero Cells) Example ~EC 5 Q (μM) TC 50 (μM) Tl (EC 50 / TC 50 ^ 60 0.5 >100 >200 57 0.81 >100 >124 56 0.7 >100 >143 208 0.26 >100 >385 217 0.32 >100 >313 139 0.4 >100 >250 150 0.85 >100 >118 93 1.3 >100 >77 Reference 0.2 >100 >500 Agent (Acyclovir) Table 4 contains the results of the antiviral efficacy (HSV: EC50, TC50 and Tl) screening results, where Tl is the therapeutic index (TC 50 EC50). TABLE 4 Antiviral Efficacy in a Yield Reduction Assay (CMV) Antiviral Efficacy (HFF Cells) Example EC50 (μM) TC 50 (μM) TI (EC 5 o/ TC 5 61 2.9 >100 >35 57 1.7 >100 >59 65 3.0 >100 >33 60 1.3 >100 >77 Reference 2.6 >100 >39 Agent (Ganciclovir) Tables 3 and 4 indicates that the compounds of the present invention have good to excellent activity in HSV infected cells from HSV pathogenecity at μM to sub-μM concentrations. While the forms of the invention herein disclosed constitute presently preferred embodiments, many others are possible. It is not intended herein to mention all of the possible equivalent forms or ramifications of the invention. It is understood that the terms used herein are merely descriptive, rather than limiting, and that various changes may be made without departing from the spirit or scope of the invention.

Claims: CLAIMS: A compound of Formula I or a pharmaceutically acceptable salt thereof I wherein: X = O, (CH 2 ) m , S, SO, SO 2 , NH, NRs or a chemical bond; Y = O, (CH 2 ) m , S, SO, SO 2 , NH, NRs; Z = N, NH, O, NHRg, NR 8 , S, SO, SO 2 ; n = an integer of from 0 to 2; m = an integer of 1,2, or 3; Ri, R 2 , R 3 , R4, R5 independently are hydrogen, halogen, hydroxyl, amino, mono or dialkylamino, cyano, nitro, alkyl groups (1-6 carbon atoms), alkoxy groups (1-6 carbon atoms), CF 3 , OCF 3 , aminoalkyl (1-6 carbon atoms), aminoaryl, Oaryl, or a heterocyclic ring having 5-7 atoms with 1-4 hetero atoms of N, O or S; Ar = phenyl, substituted phenyl, benzoheterocyclic ring, substituted benzoheterocyclic ring, heterocyclic ring, or substituted heterocyclic ring, which have substitutions Rj or R ; g and R 7 are independently hydrogen, alkyl group (1-6 carbon atoms), cycloalkyl (3- 12 carbon atoms), halogen, alkoxy, CF 3 , aminoalkyl (1-6 carbon atoms), aminoaryl, or a heterocyclic ring of from 5-7 atoms with 1-4 heteroatoms of N, O or S; e and R 7 may also form a ring, optionally cycloalkyl or aryl or substituted aryl; Rs is hydrogen, alkyl (1-6 carbon atoms), cycloalkyl (3-12 carbon atoms), phenyl or substituted phenyl wherein the substituents are as defined above. The compound of claim 1 having Formula II. π 3. The compound of claim 1 having Formula III. in 4. The compound of claim 1 having Formula IV. IV 5. The compound of claim 1 having Formula V. V 6. The compound of claim 1 having Formula VI. VI 7. The compound of claim 1 having Formula VII. substituted vπ 8. A pharmaceutical composition for the treatment of infection or disease caused by a virus, which comprises an amount of the compound of Claim 1 sufficient to provide an antivirally effective dosage of the compound of Formula I and a pharmaceutically effective carrier. 9. A pharmaceutical composition for the treatment of infection or disease caused by a virus, which comprises an amount of the compound of Claim 1 in the range of about 1 to about 50 mg/kg-day or up to 3 g per day and a pharmaceutically effective carrier. 10. A method of treatment of infection or disease caused by a virus, which comprises administering to a subject in need of such treatment a composition of Claim 1. 11. The composition of claim 8 wherein the virus is a Herpes virus. 12. The composition of claim 9 wherein the virus is a Herpes virus. 13. The method of claim 10 wherein the virus is a Herpes virus. 14. 1 (1 -Cyclopropyl-ethyl)-(2-methoxy-dibenzofuran-3 -yl)-amine 2 Cyclopentyl-(9H-fluoren-2-yl)-amine 3 (1 -Cyclopropyl-ethyl)-(9H-fluoren-2-yl)-amine 4 N 3 -Cyclopentyl-N 2 ,N 2 -dimethyl-9H-fluorene-2,3-diamine 5 Isopropyl-(2-methoxy-dib enzofuran-3 -yl)-amine 6 (2-Methoxy-dibenzofiιran-3 -yl)-(tetrahydro-thiopyran-4-yl)-amine 7 Cycloheptyl-(2-methoxy-dibenzofuran-3 -yl)-amine 8 (l-Ethyl-propyl)-(2-methoxy-dibenzofuran-3-yl)-amine 9 sec-Butyl-(2-methoxy-dibenzofuran-3 -yl)-amine 10 N 2 ,N 2 -Dimethyl-N 3 -piperidin-4-yl-9H-fluorene-2,3-diamine 11 N 3 -(l-Benzyl-butyl)-N 2 ,N 2 -dimethyl-9H-fluorene-2,3-diamine 12 (9H-Fluoren-2-yl)-piperidm-4-yl-amine 13 (l-Benzyl-butyl)-(9H-fluoren-2-yl)-amine 14 sec-Butyl-(9H-fluoren-2-yl)-amine 15 (1, l-Dioxo-hexahydro-thiopyran-4-yl)-(2-methoxy-dibenzofiιran-3-yl)-amine 16 Dibenzofuran-2-yl-(3,3,5,5-tetramethyl-cyclohexyl)-amine 17 (Decahydro-naphthalen- 1 -yl)-dibenzofuran-2-yl-amine 18 Adamantan-2-yl-dibenzofuran-2-yl-amine 19 Bicyclohexyl-4-yl-dibenzofuran-2-yl-amine 20 Bicyclo[2.2. l]hept-2-yl-dibenzofuran-2-yl-amine 21 (4-tert-Butyl-cyclohexyl)-dibenzofuran-2-yl-amine 22 Bicyclo[3.2. l]oct-2-yl-dibenzofuran-2-yl-amine 23 Cyclopentyl-dibenzofuran-2-yl-amine 24 Cyclohexyl-(2-methoxy-dibenzofuran-3 -yl)-amine 25 Cyclohexyl-(9H-fluoren-2-yl)-amine 26 Dibenzofuran-2-yl-bis-(3 -methylsulfanyl-propyl)-amine 27 Dibenzofuran-2-yl-bis-(3 -methyl-butyl)-amine 28 Dibenzofuran-2-yl-dipropyl-amine 29 N 3 -(l,l-Dioxo-hexahydro-thiopyran-4-yl)-N 2 ,N 2 -dimethyl-9H-fluorene-2,3- diamine 30 N 3 -Isoρropyl-N 2 ,N 2 -dimethyl-9H-fluorene-2,3 -diamine N 2 ,N 2 -Dimethyl-N 3 -(tetrahydro-thiopyran-4-yl)-9H-fluorene-2,3 -diamine N 3 -Cyclohexyl-N 2 ,N 2 -dimethyl-9H-fluorene-2,3 -diamine N 3 -Cycloheptyl-N 2 ,N 2 -dimethyl-9H-fluorene-2,3 -diamine N 3 -(l-Ethyl-propyl)-N 2 ,N 2 -dimethyl-9H-fluorene-2,3-diamine N 3 -(l-Cyclopropyl-ethyl)-N 2 ,N 2 -dimethyl-9H-fluorene-2,3-diamine N 3 -sec-Butyl-N 2 ,N 2 -dimethyl-9H-fluorene-2,3-diamine (9H-Fluoren-2-yl)-isopropyl-amine (9H-Fluoren-2-yl)-(tetrahydro-thiopyran-4-yl)-amine Cycloheptyl-(9H-fluoren-2-yl)-amine Dibenzofuran-2-yl-( 1 , 1 -dioxo-hexahydro-thiopyran-4-yl)-amine Dibenzofuran-2-yl-piperidin-4-yl-amine Dibenzofuran-2-yl-isopropyl-amine Cy clohexyl-dib enzofuran-2-yl-amine (1 -Cyclopropyl-ethyl)-dibenzofuran-2-yl-amine Dibenzofuran-3-yl-(l, l-dioxo-hexahydro-thiopyran-4-yl)-amine Dibenzofuran-3 -yl-piperidin-4-yl-amine Dibenzofuran-3 -yl-isopropyl-amine Dibenzofuran-3 -yl-(tetrahydro-thiopyran-4-yl)-amine Cyclohexyl-dibenzofuran-3 -yl-amine Cycloheptyl-dibenzofiιran-3 -yl-amine (4-Chloro-benzyl)-dibenzofuran-2-yl-amine (4-Chloro-3-nitro-benzyl)-dibenzofuran-2-yl-amine Dibenzofuran-2-yl-(3 -trifluoromethoxy-benzyl)-amine Benzo[l,3]dioxol-5-ylmethyl-dibenzofuran-2-yl-amine Dibenzofuran-2-yl-(2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)-amine Dibenzofuran-2-yl-(3,5-dimethoxy-benzyl)-amine Dibenzofuran-2-yl-(4-trifluoromethyl-benzyl)-amine Dibenzofuran-2-yl-(2-methyl-benzyl)-amine Dibenzofuran-2-yl-thiophen-3 -ylmethyl-amine Dibenzofuran-2-yl-(4-nitro-benzyl)-amine Dibenzofiιran-2-yl-(4-methylsulfanyl-benzyl)-amine Dibenzofuran-2-yl-(4-methyl-benzyl)-amine Benzyl-dibenzofuran-2-yl-amine (3-Benzyloxy-benzyl)-dibenzofuran-2-yl-amine (l-Benzyl-butyl)-dibenzofuran-2-yl-amine Dibenzofuran-2-yl-[2-(2-methoxy-phenyl)-l-methyl-ethyl]-amine 3 -(Dibenzofuran-2-ylamino)-2-methyl-butan- 1 -ol Dibenzofuran-2-yl-(l-ethyl-butyl)-amine Dibenzofuran-2-yl-(l-ethyl-propyl)-amine Dibenzofiιran-2-yl-(l,3-dimethyl-butyl)-amine (l-Cyclohexyl-ethyl)-dibenzofuran-2-yl-amine Cyclooctyl-dibenzofuran-2-yl-amine Cycloheptyl-dibenzofuran-2-yl-amine Dibenzofuran-2-yl-(tetrahydro-thiopyran-4-yl)-amine Dibenzofuran-2-yl-(tetrahydro-thiophen-3 -yl)-amine Dibenzofuran-2-yl-(l,2-dimethyl-propyl)-amine Dibenzofuran-2-yl-( 1 -methyl-butyl)-amine sec-Butyl-dibenzofuran-2-yl-amine Benzofurp[3,2-b]pyridin-8-yl-(2-fluoro-benzyl)-amine Benzofuro [3 ,3 -b]pyridin-8-yl-pyridin-4-ylmethyl-amine Benzofuro[3,2-b]pyridin-8-yl-(2-methyl-benzyl)-amine N-(2-Fluoro-benzyl)-N'-methyl-dibenzofuran-2,8-diamine N-Methyl-N' -quinolin-4-ylmethyl-dibenzofuran-2, 8-diamine N-Methyl-N' -naphthanlen- 1 -ylmethyl-dib enzofuran-2, 8-diamine N-(4-Methanesulfonyl-benzyl)-N'-methyl-diebnzofuran-2,8-diamine N-Methyl-N' -pyridin-4-ylmethyl-dibensofuran-2, 8-diamine N-Methyl-N' -(2-methyl-benzyl)-dibenzofuran-2, 8-diamine Naphthanlen- 1 -ylmethyl-( 10H-phenothiazin-2-yl)-amine (4-Methanesulfonyl-benzyl)-(l 0H-phenothiazin-2-yl)-amine (3 -Fluoro-2-methyl-benzyl)-( 10-oxa-9-thia- 1 -aza-anthracen-6-yl)-amine (2-Fluoro-2-methyl-benzyl)-(10-oxa-9-thia-l-aza-anthracen-6-yl)-amine (10-Oxa-9-thia- 1 -aza-anthracen-6-yl)-qinolin-4-ylmethyl-amine Naphthalene- 1 -ylmethyl-( 10-oxa-9-thia- 1 -aza-anthracen-6-yl)-amine (4-Methanesulfonyl-benzyl)-(l 0-oxa-9-thia- 1 -aza-anthracen-6-yl)-amine (10-Oxa-9-thia- l-aza-anthracen-6-yl)-pyridin-4-ylmethyl-amine (2-Methyl-b enzyl)-( 10-oxa-9-thia- 1 -aza-anthracen-6-yl)-amine 97 Anthracen-2-yl-quinolin-4-ylmethyl-amine 98 Anthracen-2-yl-(4-methanesulfonyl-benzyl)-amine 99 Anthracen-2-yl-pyridin-4-ylmethyl-amine 100 Anthracen-2-yl-(2-methyl-benzyl)-amine 101 Dibenzo[b,e][l,4]-dioxin-2-yl-(2-fluoro-benzyl)-amine 102 Dibenzo [b,e][l, 4] dioxin-2-yl-(2-fluoro-benzyl)-amine 103 Dibenzo[b,e][l,4]fioxin-2-yl-quinolin-4-ylmethyl-amine 104 Dibenzo[b,e][l,4]fioxin-2-yl-naphthalen-l-ylmethyl-amine 105 Dibenzo [b, e] [ 1 ,4]fioxin-2-yl-(4-methanesulfonyl-b enzyl)-amine 106 Dibenzo[b,e][l,4]fioxin-2-yl-pyridin-4-ylmethyl-amine 107 8-(3-Fluoro-2-methyl-benzylamino)-dibenzofuran-2-ol 108 8-(2-Fluoro-benzylamino)-dibenzofuran2-ol 109 8-(4-Methanesulfonyl-benzylamino)-dibenzofuran-2-ol 110 8-[(Pyridin-4-ylmethyl)-amino]-dibenzofuran-2-ol 111 8-(2-Methyl-benzylamino)-dibenzofuran-2-ol 112 (8-Chloro-dibenzofuran-2-yl)-(2-fluoro-benzyl)-amine 113 8-Chloro-dibenzofuran-2-yl)-naphthalen- 1 -ylmethyl-amine 114 8-Chloro-dibenzofuran-2-yl)-(4-methanesulfonyl-benzyl)-amine 115 (4-Methanesulfonyl-benzyl)-(6,7,8,9-tetrahydro-5H-carbazol-3-yl)-amine 116 Pyridin-4-ylmethyl-(6,7j 8,9-tetrahydro-5H-carbazol-3 -yl)-amine 117 Benzofuro[3,2-b]pyridin-8-yl-(3-fluoro-2-methyl-benzyl)-amine 118 Dibenzofuran-2-yl-quinolin-4-ylmethyl-amine 119 Dibenzofuran-2-yl-quinolin-2-ylmethyl-amine 120 (4-Dimethylamino-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 121 Dibenzofuran-2-yl-(4-dimethylamino-benzyl)-amine 122 Diebnzofuran-2-yl-(5-nitro-thiophen-2-ylmethyl)-amine 123 Dibenzofuran-2-yl-thiazol-2-ylmethyl-amine 124 Benzyl-(8-fluoro-dibenzofuran-2-yl)-amine 125 N-(-3-Methoxybenzyl)-N'-methyl-dibenzofuran-2,8-diamine 126 N-(3,5-Dimethoxy-benzyl)-N'-methyl-dibenzofiιran-2,8-diamine 127 N-(4-tert-Butyl-benzyl)-N'-methyl-dibenzofuran-2, 8-diamine 128 N-Benzyl-N' -methyl-dibenzofuran-2, 8-diamine 129 2-[(8-Methylamino-dibenzofuran-2-ylamino)-methyl]-benzonitrile 130 (4-Methoxy-b enzyl)-phenoxathiin-3 -yl-amine 131 (8-Chloro-dibenzofuran-2-yl)-(3 -methoxy-benzyl)-amine 132 (3 -Methoxy-benzyl)-phenoxathiin-3 -yl-amine 133 (3,5 -Dimethoxy-b enzyl)-phenoxathiin-3 -yl-amine 134 (3 -Fluoro-4-methoxy-benzyl)-phenoxathiin-3 -yl-amine 135 (4-tert-Butyl-benzyl)-phenoxathiin-3 -yl-amine 136 Benzyl-phenoxathiin-3 -yl-amine 137 (2-Ethoxy-benzyl)-phenoxathiin-3 -yl-amine 138 (8-Chloro-dibenzofuran-2-yl)-(3 , 5-dimethoxy-benzyl)-amine 139 (8-Chloro-dibenzofuran-2-yl)-(3-fluoro-4-methoxy-benzyl)-amine 140 Benzyl-(8-chloro-dibenzofuran-2-yl)-amine 141 (9H-Fluoren-2-yl)-(4-methoxy-benzyl)-amine 142 (8-Chloro-dibenzofuran-2-yl)-thiazol-2-ylmethyl-amine 143 (9H-Fluoren-2-yl)-(3-methoxy-benzyl)-amine 144 (3,5-Dimethoxy-benzyl)-(9H-fluoren-2-yl)-amine 145 (9H-Fluoren-2-yl)-(3 -fluoro-4-methoxy-benzyl)-amine 146 (4-tert-Butyl-benzyl)-(9H-fluoren-2-yl)-amine 147 Benzyl-(9H-fluoren-2-yl)-amine 148 (9H-Fluoren-2-yl)-thiazol-2-ylmethyl-amine 149 (2-Ethoxy-benzyl)-(9H-fluoren2-yl-amine 150 Dibenzofiιran-4-yl-(4-methoxy-benzyl)-amine 151 2-[(8-Chloro-dibenzofuran-2-ylamino)-methyl]-benzonitrile 152 Dibenzofuran-4-yl-(3-methoxy-benzyl)-amine 153 Dibenzofuran-4-yl-(3 , 5 -dimethoxy-benzyl)-amine 154 Dibenzofuran-4-yl-(3-fluoro-4-methoxy-benzyl)-amine 155 (4-tert-Butyl-benzyl)-dibenzofuran-4-yl-amine 156 Dibenzofuran-4-yl-(2-ethoxy-benzyl)-amine 157 N-(4-Methoxy-benzyl)-N' -methyl-dibenzofuran-2, 8-diamine 158 (8-Chloro-dibenzofuran-2-yl)(4-methoxy-benzyl)-amine 159 (8-Chloro-dibenzofuran-2-yl)-(2-ethoxy-benzyl)-amine 160 Dibenzofuran-4-yl-(2,4-dimethyl-benzyl)-amine 161 N-Methyl-N'-thiophen-3 -ylmethyl-dibenzofuran-2, 8-diamine 162 N-Methyl-N'-pyridin-2-ylmethyl-dibenzofuran-2, 8-diamine 163 (2-Bromo-benzyl)-phenoxathiin-3 -yl-amine 164 Phenoxathiin-3 -yl-quinolin-4-ylmethyl-amine 165 Phenoxathiin-3 -yl-thiophen-3 -ylmethyl-amine 166 (3 -Methyl-pyridin-2-ylmethyl)-phenoxathiin-3 -yl-amine 167 Phenoxathiin-3 -yl-p yridin-3 -ylmethyl-amine 168 Phenoxathiin-3 -yl-pyridin-2-ylmethyl-amine 169 (8-Chloro-dibenzofuran-2-yl)-thiophen-3 -ylmethyl-amine 170 (2-Bromo-benzyl)-(9-ethyl-9H-carbazol-3-yl)-amine 171 (8-Chloro-dibenzofuran-2-yl)-(3 -methyl-pyridin-2-ylmethyl)-amine 172 (9-Ethyl-9B-carbazol-3 -yl)-thiophen-3 -ylmethyl-amine 173 (5-Chloro-thiophen-2-ylmethyl)-(9-ethyl-9H-carbazol-3-yl)-amine 174 (9-Ethyl-9H-carbazol-3 -yl)-pyridin-3 -ylmethyl-amine 175 (2-Bromo-benzyl)-(9B-fluoren-2-yl)-amine 176 (8-Chloro-dibenzofuran-2-yl)-pyridin-4-ylmethyl-amine 177 (9H-Fluoren-2-yl)-quinolin-2-ylmethyl-amine 178 (9H-Fluoren-2-yl)-thiophen-3 -ylmethyl-amine 179 (9H-Fluoren-2-yl)-(3-methyl-pyridin-2-ylmethyl)-amine 180 (9H-Fluoren-2-yl)-pyridin-4-ylmethyl-amine 181 (9B-Fluoren-2-yl)-pyridin-3 -ylmethyl-amine 182 (9H-Fluoren-2-yl)-pyridin-2-ylmethyl-amine 183 (8-Chloro-dibenzofuran-2-yl)-pyridin-3 -ylmethyl-amine 184 Dibenzofuran-4-yl-quinolin-4-ylmethyl-amine 185 Dibenzofuran-4-yl-quinolin-2-ylmethyl-amine 186 Dibenzofuran-4-yl-thiophen-3 -ylmethyl-amine 187 Dibenzofuran-4-yl-(3-methyl-pyridin-2-ylmethyl)-amine 188 Dibenzofuran-4-yl-pyridin-4-ylmethyl-amine 189 Diberϊzofuran-4-yl-pyridin-3 -ylmethyl-amine 190 Dibenzofuran-4-yl-pyridin-2-ylmethyl-amine 191 (2-Bromo-benzyl)-(8-chloro-dibenzofuran-2-yl)-amine 192 (8-Chloro-dibenzofuran-2-yl)-pyridin-2-ylmethyl-amine 193 N-Methyl-N'-(2,3,6-trifluoro-benzyl)-dibenzofuran-2,8-diamine 194 N-Methyl-N'-(2,3,4-trifluoro-benzyl)-dibenzofuran-2,8-diamine 195 N-(2,6-Difluoro-benzyl)-N'-methyl-dibenzofuran-2,8-diamine 196 N-(2,5-Difluoro-benzyl)-N'-methyl-dibenzofuran-2,8-diamine 197 N-(2,4-Difluoro-benzyl)-N'-methyl-dibenzofiiran-2, 8-diamine 198 N-(2,3 -Difluoro-benzyl)-N'-methyl-dibenzoJ__uran-2, 8-diamine 199 N-(2,5-Dimethyl-benzyl)-N'-methyl-dibenzofuran-2,8-diamine 200 N-(2,4-Dimethyl-benzyl)-N l -methyl-dibenzofuran-2, 8-diamine 201 N-(2,3-Dihydro-benzo[l,4]dioxin-6-ylmethyl)-N'-methyl-dibenzofuran-2,8- diamine 202 (3 -Fluoro-2-methyl-benzyl)-phenoxathiin-3 -yl-amine 203 (8-Chloro-dibenzofuran-2-yl)-(2,3,6-trifluoro-benzyl)-amine 204 Phenoxathiin-3 -yl-(2,3 ,6-trifluoro-benzyl)-amine 205 Phenoxathiin-3 -yl-(2,3 ,4-trifluoro-benzyl)-amine 206 (2,6-Difluoro-benzyl)-phenoxathiin-3-yl-amine 207 (2, 5 -Difluoro-benzyl)-phenoxathiin-3 -yl-amine 208 (2,4-Difluoro-benzyl)-phenoxathiin-3 -yl-amine 209 (2,3 -Difluoro-benzyl)-phenoxathiin-3 -yl-amine 210 (2,4-Dimethyl-benzyl)-phenoxathiin-3 -yl-amine 211 (2,3 -Dihy dro-benzo [ 1 ,4]dioxin-6-ylmethyl)-phenoxathiin-3 -yl-amine 212 Benzo[b]thiophen-5-yl-(3-fluoro-2-methyl-benzyl)-amine 213 (8-Chloro-dibenzofuran-2-yl)-(2,3 ,4-trifluoro-benzyl)-amine 214 (8-Chloro-dibenzofuran-2-yl)-(2,6-difluoro-benzyl)-amine 215 (8-Chloro-dibenzofuran-2-yl)-(2, 5-difluoro-benzyl)-amine 216 (8-Chloro-dibenzofuran-2-yl)-(2,4-difluoro-benzyl)-amine 217 (9-Ethyl-9H-carbazol-3 -yl)-(3 -fluoro-2-methyl-benzyl)-amine 218 (8-Chloro-dibenzofuran-2-yl)-(2,3 -difluoro-benzyl)-amine 219 (9-Ethyl-9H-carbazol-3-yl)-(2,3,6-trifluoro-benzyl)-amine 220 (9-Ethyl-9H-carbazol-3-yl)-(2,3,4-trifluoro-benzyl)-amine 221 (2,6-Difluoro-benzyl)-(9-ethyl-9H-carbazol-3-yl)-amine 222 (2,5-Difluoro-benzyl)-(9-ethyl-9H-carbazol-3-yl)-amine 223 (2,4-Difluoro-benzyl)-(9-ethyl-9H-carbazol-3-yl)-amine 224 (2,3-Difluoro-benzyl)-(9-ethyl-9H-carbazol-3-yl)-amine 225 (2,5-Dimethyl-benzyl)-(9-ethyl-9H-carbazol-3-yl)-amine 226 (2,4-Dimethyl-benzyl)-(9-ethyl-9B-carbazol-3-yl)-amine 227 (2,3-Dihydro-benzo[l,4]dioxin-6-ylmethyl)-(9-ethyl-9B-carbazol-3-yl)-amine 228 (9B-Fluoren-2-yl)-(3 -fluoro-2-methyl-benzyl)-amine 229 (8-Chloro-dibenzofuran-2-yl)-(2,5-dimethyl-benzyl)-amine 230 (9B-Fluoren-2-yl)-(2,3 ,6-trifluoro-benzyl)-amine 231 (9H-Fluoren-2-yl)-(2,3 ,4-trifluoro-benzyl)-amine 232 (2,5-Difluoro-benzyl)-(9H-fluoren-2-yl)-amine 233 (2,4-Difluoro-benzyl)-(9H-fluoren-2-yl)-amine 234 (2,3 -Difluoro-benzyl)-(9H-fluoren-2-yl)-amine 235 (2,5-Dimethyl-benzyl)-(9H-fluoren-2-yl)-amine 236 (2,4-Dimethyl-benzyl)-(9H-fluoren-2-yl)-amine 237 (2,3-Dihydro-benzo[l,4]dioxin-6-ylmethyl)-(9H-fluoren-2-yl)-amine 238 (8-Chloro-dibenzofuran-2-yl)-(2,4-dimethyl-benzyl)-amine 239 Dibenzofuran-4-yl-(2, 5-dimethyl-benzyl)-amine 240 Dibenzofuran-4-yl-(3 -fluoro-2-methyl-benzyl)-amine 241 N-(3-Fluoro-2-methyl-benzyl)-N'-methyl-dibenzofuran-2,8-diamine 242 (8-Chloro-dibenzofuran-2-yl)-(3 -fluoro-2-methyl-benzyl)-amine 243 (8-Chloro-dibenzofuran-2-yl)-(2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)-amine 244 (2,5-Dimethoxy-benzyl)-phenoxathiin-3-yl-amine 245 (2,3 -Dimethoxy-benzyl)-phenoxathiin-3 -yl-amine 246 (2-Chloro-benzyl)-phenoxathiin-3 -yl-amine 247 (2-Methoxy-benzyl)-phenoxathiin-3 -yl-amine 248 (2-Methyl-benzyl)-phenoxathiin-3 -yl-amine 249 Anthracen-2-yl-(2-chloro-benzyl)-amine 250 Anthracen-2-yl-(2-fluoro-benzyl)-amine 251 Dibenzo[ 1 ,4]dioxin-2-yl-(2,3 -dimethoxy-benzyl)-amine 252 (2-Chloro-benzyl)-dibenzo[ 1 ,4]dioxin-2-yl-amine 253 2-(Dibenzo[l,4]dioxin-2-ylaminomethyl)-phenol 254 Dibenzo[l,4]dioxin-2-yl-(2-methoxy-benzyl)-amine 255 2-[(9-Ethyl-9H-carbazol-3-ylamino)-methyl]-phenol 256 (9-Ethyl-9H-carbazol-3 -yl)-(2-fluoro-benzyl)-amine 257 (9-Ethyl-9H-carbazol-3-yl)-(2-methyl-benzyl)-amine 258 (2-Chloro-benzyl)-(9H-fluoren-2-yl)-amine 259 2-[(9H-Fluoren-2-ylamino)-methyl]-phenol 260 (9H-Fluoren-2-yl)-(2-methoxy-benzyl)-amine 261 (9H-Fluoren-2-yl)-(2-trifluoromethyl-benzyl)-amine 262 (9H-Fluoren-2-yl)-(2-fluoro-benzyl)-amine 263 Dibenzofiιran-4-yl-(2,5-dimethoxy-benzyl)-amine 264 Dibenzofuran-4-yl-(2,3 -dimethoxy-benzyl)-amine 265 2-(Dibenzofuran-4-ylaminomethyl)-phenol 266 Dibenzofiiran-4-yl-(2-methoxy-benzyl)-amine 267 (2,5-Dimethoxy-benzyl)-(3-methoxy-dibenzofuran-2-yl)-amine 268 (2,3 -Dimethoxy-benzyl)-(3 -methoxy-dibenzofiιran-2-yl)-amine 269 (2-Methoxy-benzyl)-(3-methoxy-dibenzofiιran-2-yl)-amine 270 Dibenzofuran-2-yl-(2,5-dimethoxy-benzyl)-amine 271 Dibenzofuran-2-yl-(4-methoxy-benzyl)-amine 272 (2-Bromo-benzyl)-dibenzofuran-2-yl-amine 273 (8-Fluoro-dibenzofuran-2-yl)-(3H-imidazol-4-ylmethyl)-amine 274 2-[(8-Fluoro-dibenzofuran-2-ylamino)-methyl]-benzonitrile 275 (2-Ethoxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 276 (8-Fluoro-dibenzofuran-2-yl)-(4-methylsulfanyl-benzyl)-amine 277 (2-Bromo-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 278 (8-Fluoro-dibenzofuran-2-yl)-quinolin-4-ylmethyl-amine 279 (8-Fluoro-dibenzofuran-2-yl)-quinolin-2-ylmethyl-amine 280 Dibenzofuran-2-yl-naphthalen- 1 -ylmethyl-amine 281 (8-Fluoro-dibenzofuran-2-yl)-naphthalen-2-ylmethyl-amine 282 (8-Fluoro-dibenzofuran-2-yl)-naphthalen- 1 -ylmethyl-amine 283 Dibenzofuran-2-yl-(2-nitro-benzyl)-amine 284 Dibenzofuran-2-yl-(3H-imidazol-4-ylmethyl)-amine 285 2-(Dibenzofuran-2-ylaminomethyl)-benzonitrile 286 Dibenzofuran-2-yl-(2-ethoxy-benzyl)-amine 287 Dibenzofuran-2-yl-(3 -trifluoromethyl-benzyl)-amine 288 (4-tert-Butyl-benzyl)-dibenzofuran-2-yl-amine 289 Dibenzofuran-2-yl-(3-fluoro-benzyl)-amine 290 (2,5-Dimethoxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 291 (2,3-Dimethoxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 292 (4-Benzyloxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 293 (3 -Benzyloxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 294 (4-Chloro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 295 (3-Chloro-benzyl)-(8-fluoro-dibenzofiιran-2-yl)-amine 296 (2-Chloro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 297 4-[(8-Fluoro-dibenzofuran-2-ylamino)-methyl]-phenol 298 3-[(8-Fluoro-dibenzofuran-2-ylamino)-methyl]-phenol 299 Dibenzofuran-2-yl-(2-fluoro-benzyl)-amine 300 (8-Fluoro-dibenzofuran-2-yl)-(4-methoxy-benzyl)-amine 301 (8-Fluoro-dibenzofuran-2-yl)-(3 -methoxy-benzyl)-amine 302 (8-Fluoro-dibenzofuran-2-yl)-(2-methoxy-benzyl)-amine 303 (8-Fluoro-dibenzofuran-2-yl)-(4-trifluoromethyl-benzyl)-amine 304 (8-Fluoro-dibenzofuran-2-yl)-(3 -trifluoromethyl-benzyl)-amine 305 (4-tert-Butyl-benzyl)-(8-fluoro-dibenzofiιran-2-yl)-amine 306 (4-Fluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 307 (3 -Fluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 308 (2-Fluoro-benzyl)-(8-fluoro-dibenzofijran-2-yl)-amine 309 (8-Fluoro-dibenzofuran-2-yl)-(4-methyl-benzyl)-amine 310 (8-Fluoro-dibenzofuran-2-yl)-(3 -methyl-benzyl)-amine 31 1 Dibenzofuran-2-yl-(2,6-dimethoxy-benzyl)-amine 312 Dibenzofuran-2-yl-(2,4-dimethoxy-benzyl)-amine 313 Dibenzofuran-2-yl-(2,3 -dimethoxy-benzyl)-amine 314 (4-Benzyloxy-benzyl)-dibenzofiιran-2-yl-amine 315 Dibenzofuran-2-yl-(3 -methyl-b enzyl)-amine 316 (3 -Chloro-benzyl)-dibenzofuran-2-yl-amine 317 3 -(Dibenzofuran-2-ylaminomethyl)-phenol 318 (2-Chloro-benzyl)-dibenzofuran-2-yl-amine 319 Dibenzofuran-2-yl-(3 -methoxy-benzyl)-amine 320 Dibenzofuran-2-yl-(2-methoxy-benzyl)-amine 321 (9H-Fluoren-2-yl)-(2-methyl-benzyl)-amine 322 Dibenzofuran-4-yl-(2-methyl-benzyl)-amine 323 (8-Chloro-dibenzofuran-2-yl)-(2-methyl-benzyl)-amine 324 (2-Methyl-benzyl)-(10H-ρhenothiazin-2-yl)-amine 325 Dibenzo[b,e][l,4]dioxin-2-yl-(2-methyl-benzyl)-amine 326 Dibenzofuran-2-yl-(2, 6-difluoro-benzyl)-amine 327 Dibenzofuran-2-yl-(2,5-difluoro-benzyl)-amine 328 Dibenzofuran-2-yl-(2,4-difluoro-benzyl)-amine 329 Dibenzofuran-2-yl-(2,3 -difluoro-benzyl)-amine 330 (8-Fluoro-dibenzofuran-2-yl)-thiophen-2-ylmethyl-amine 331 Dibenzofuran-2-yl-(2,5-dimethyl-benzyl)-amine 332 (8-Fluoro-dibenzofuran-2-yl)-thiophen-3 -ylmethyl-amine 333 (8-Fluoro-dibenzofuran-2-yl)-furan-2-ylmethyl-amine 334 (8-Fluoro-dibenzofuran-2-yl)-furan-3 -ylmethyl-amine 335 (8-Fluoro-dibenzofuran-2-yl)-(6-methyl-pyridin-2-ylmethyl)-amine 336 (8-Fluoro-dibenzofuran-2-yl)-(4-methanesulfonyl-benzyl)-amine 337 (8-Fluoro-dibenzofuran-2-yl)-pyridin-4-ylmethyl-amine 338 (8-Fluoro-dibenzofuran-2-yl)-pyridin-3 -ylmethyl-amine 339 (8-Fluoro-dibenzofuran-2-yl)-pyridin-2-ylmethyl-amine 340 (8-Fluoro-dibenzofuran-2-yl)-(3-fluoro-4-methoxy-benzyl)-amine 341 Dibenzofuran-2-yl-(2,4-dimethyl-benzyl)-amine 342 (8-Fluoro-dibenzofuran-2-yl)-(3-fluoro-2-methyl-benzyl)-amine 343 (8-Fluoro-dibenzofuran-2-yl)-(2,3,6-trifluoro-benzyl)-amine 344 (8-Fluoro-dibenzofuran-2-yl)-(2,3 ,4-trifluoro-benzyl)-amine 345 (3,5-Difluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 346 (3 ,4-Difluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 347 (3,5-difluoro-benzyl)-(8-fluoro-dibenzofiiran-2-yl)-amine 348 (2,6-Difluoro-benzyl (2,5-Difluoro-benzyl)-(8-fluoro-dibenzofiιran-2-yl)-amine 349 (2,4-Difluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 350 (2,3 -Difluoro-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 351 (2, 5-Dimethyl-benzyi)-(8-fluoro-dibenzofuran-2-yl)-amine 352 (2,4-Dimethyl-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 353 (2,3 -Dihydro- 1 ,4-benzodioxin-6-ylmethyl)-(8-fluoro-dibenzofuran-2-yl)-amine 354 (3,5-Dimethoxy-benzyl)-(8-fluoro-dibenzofuran-2-yl)-amine 355 Dibenzofuran-2-yl-furan-2-ylmethyl-amine 356 Dibenzofuran-2-yl-furan-3 -ylmethyl-amine 357 Dibenzofiiran-2-yl-(6-methyl-pyridin-2-ylmethyl)-amine 358 Dibenzofuran-2-yl-(4-methanesulfonyl-benzyl)-amine 359 Dibenzofuran-2-yl-pyridin-4-ylmethyl-amine 360 Dibenzofuran-2-yl-pyridin-3 -ylmethyl-amine 361 Dibenzofuran-2-yl-pyridin-2-ylmethyl-amine 362 Dibenzofuran-2-yl-(3-fluoro-4-methoxy-benzyl)-amine 363 Dibenzofuran-2-yl-(3 -fluoro-2-methyl-benzyl)-amine 364 Dibenzofuran-2-yl-(2, 3 , 6-trifluoro-benzyl)-amine 365 Dibenzofuran-2-yl-(2,3 ,4-trifluoro-benzyl)-amine 366 Dibenzofuran-2-yl-(3 , 5 -difluoro-benzyl)-amine 367 Dibenzofuran-2-yl-(3,4-difluoro-benzyl)-amine 368 Dibenzofiιran-2-yl-(3 ,4-dimethoxy-benzyl)-amine 369 Dibenzofuran-2-yl-methyl-(2-methyl-benzyl)-amine 370 Dibenzothiohen-2-yl-(2,4-dimethyl-benzyl)-amine 371 (4-tert-Butyl-benzyl)-dibenzothiohen-2-yl-amine 372 (2-Chloro-benzyl)-dibenzothiohen-2-yl-amine 373 Dibenzothiohen-2-yl-(2,6-difluoro-benzyl)-amine 374 Dibenzothiohen-2-yl-(2,3,6-trifluoro-benzyl)-amine 375 Dibenzothiohen-2-yl-(2-fluoro-benzyl)-amine 376 Benzyl-dibenzothiohen-2-yl-amine 377 Dibenzothiohen-2-yl-(4-methoxy-benzyl)-amine 378 Dibenzothiohen-2-yl-(2, ' 3-dimethoxy-benzyl)-amine 379 Dibenzothiohen-2-yl-(2,5-difluoro-benzyl)-amine 380 Dibenzothiohen-2-yl-(3 -methoxy-benzyl)-amine 381 Dibenzothiohen-2-yl-(2,3 ,4-trifluoro-benzyl)-amine 382 (-2-Bromo-benzyl)-dibenzothiohen-2-yl-amine 383 Dibenzothiohen-2-yl-(2,3-dihydro-l,4-benzodioxin-6-ylmethyl)-amine 384 Dibenzothiohen-2-yl-(3 -fluoro-4-methoxy-benzyl)-amine 385 Dibenzothiohen-2-yl-(2,5-dimethyl-benzyl)-amine 386 Dibenzothiohen-2-yl-thiophen-3 -ylmethyl-amine 387 Dibenzothiohen-2-yl-naphthalene- 1 -ylmethyl-amine 388 Dibenzothiohen-2-yl-(2-trifluoromethyl-benzyl)-amine 389 Dibenzothiohen-2-yl-naphthalen-2-ylmethyl-amine 390 Dibenzothiohen-2-yl-(2-ethoxy-benzyl)-amine 391 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(3-fluoro-2-methyl-benzyl)-amine 392 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2-methyl-benzyl)-amine 393 (10, 1 l-Dihydro-5B-dibenz[b,f]azepin-2-yl)-(2,4-dimethyl-benzyl)-amine 394 (4-tert-Butyl-benzyl)-(10, 1 l-dihydro-5B-dibenz[b,f]azeρin-2-yl)-amine 395 (2-Chloro-benzyl)-(10, 1 l-dihydro-5H-dibenz[b,f]azepin-2-yl)-amine 396 (2,6-Difluoro-benzyl)-(10, 1 l-dihydro-5H-dibenz[b,f]azepin-2-yl)-amine 397 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2,3,6-trifluoro-benzyl)-amine 398 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2-fluoro-benzyl)-amine 399 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(3,5-dimethoxy-benzyl)-amine 400 Benzyl-(10, 1 l-dihydro-5H-dibenz[b,f]azepin-2-yl)-amine 401 (10, 1 l-Dihydro-5B-dibenz[b,f]azepin-2-yl)-(4-methoxy-benzyl)-amine 402 (10, 1 l-Dihydro-5B-dibenz[b,f]azepin-2-yl)-(2,3-dimethoxy-benzyl)-amine 403 (2, 5-difluoro-benzyl)-(l 0, 11 -dihydro-5H-dibenz[b,f] azepin-2-yl)-amine 404 (10,ll-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(3-methoxy-benzyl)-amine 405 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2,3,4-trifluoro-benzyl)-amine 406 (2-Bromo-benzyl)-(10, 1 l-dihydro-5H-dibenz[b,f]azepin-2-yl)-amine 407 (2,3-Dihydro-l,4-benzodioxin-6-ylmethyl)-(10,ll-dihydro-5H- dibenz[b,f]azepin-2-yl)-amine 408 (10,ll-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(3-fluoro-4-methoxy-benzyl)-amine 409 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2,5-dimethyl-benzyl)-amine 410 (10, 1 l-Dihydro-5B-dibenz[b,f]azepin-2-yl)-thiophen-3-ylmethyl-amine 411 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-naphthalen-l-ylmethyl-amine 412 (10,ll-Dihydro-5H-dibenz[b,f]azepin-2-yl)-(2-trifluoromethyl-benzyl)-amine 413 (10, 1 l-Dihydro-5H-dibenz[b,f]azepin-2-yl)-naphthalen-2-ylmethyl-amine 414 (10, 1 l-Dihydro-5B-dibenz[b,fjazepin-2-yl)-(2-ethoxy-benzyl)-amine 415 (3-Fluoro-2-methyl-benzyl)-(10H-phenothiazin-2-yl)-amine 416 (2,4-Dimethyl-benzyl)-(10H-phenothiazin-2-yl)-amine 417 (4-tert-Butyl-benzyl)-(10B-phenothiazin-2-yl)-amine 418 (2-Chloro-benzyl)-(10H-phenothiazin-2-yl)-amine 419 (2, 6-Difluoro-benzyl)-(l 0H-phenothiazin-2-yl)-amine 420 (10H-Phenothiazin-2-yl)-(2,3,6-trifluorobenzyl)-amine 421 (2-Fluoro-benzyl)-(10H-phenothiazin-2-yl)-amine 422 (3 , 5-Dimethoxy-benzyl)-(l 0H-phenothiazin-2-yl)-amine 423 Benzyl-( 10H-ρhenothiazin-2-yl)-amine 424 (4-Methoxy-benzyl)-(10B-phenothiazin-2-yl)-amine 425 (2,5-Difluoro-benzyl)-(10H-phenothiazin-2-yl)-amine 426 (10H-Phenothiazin-2-yl)-(2,3,4-trifluoro-benzyl)-amine 427 (2,3-Dihydro-l,4-benzodioxin-6-ylmethyl)-(10B-phenothiazin-2-yl)-amine 428 (3-Fluoro-4-methoxy-benzyl)-(10H-phenothiazin-2-yl)-amine 429 (2,5-Dimethyl-benzyl)-(10H-phenothiazin-2-yl)-amine 430 (10H-Phenothiazin-2-yl)-thiophen-3 -ylmethyl-amine 431 (10H-Phenothiazin-2-yl)-(2-trifluoromethyl-benzyl)-amine 432 (9H-Carbazol-3 -yl)-(3 -fluoro-2-methyl-benzyl)-amine 433 (9H-Carbazol-3-yl)-(2-methyl-benzyl)-amine 434 (9H-Carbazol-3 -yl)-(2,4-dimethyl-benzyl)-amine 435 (4-tert-Butyl-benzyl)-(9H-carbazol-3-yl)-amine 436 (9H-Carbazol-3 -yl)-(2-chloro-benzyl)-amine 437 (9H-Carbazol-3 -yl)-(2,6-difluoro-benzyl)-amine 438 (9H-Carbazol-3-yl)-(2,3,6-trifluoro-benzyl)-amine 439 (9H-Carbazol-3 -yl)-(3 , 5 -dimethoxy-benzyl)-amine 440 (9H-Carbazol-3 -yl)-(2, 3 -dimethoxy-benzyl)-amine 441 (9H-Carbazol-3 -yl)-(2, 5 -difluoro-benzyl)-amine 442 (9H-Carbazol-3 -yl)-(2,3 ,4-trifluoro-benzyl)-amine 443 (9H-Carbazol-3-yl)-(2,3-dihydro-l,4-benzodioxin-6-ylmethyl)-amine 444 (9H-Carbazol-3 -yl)-(2, 5 -dimethyl-b enzyl)-amine 445 (9H-Carbazol-3 -yl)-naphthalen- 1 -ylmethyl-amine 446 (9H-Carbazol-3 -yl)-naphthalen-2-ylmethyl-amine 447 Dibenzofuran-2-yl-bis-(2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)-amine 448 Dibenzofuran-2-yl-bis-thiophen-3 -ylmethyl-amine 449 Dibenzofuran-2-yl-(4-phenoxy-benzyl)-amine 450 2-Dibenzofuran-2-yl-2,3 -dihydro- lH-isoindole 451 2-Dibenzofuran-2-yl~ IH-isoindole- 1 , 3 -dione 452 Dibenzofuran-2-yl-(4-trifluoromethoxy-benzyl)-amine 453 Dibenzofuran-2-yl-(2-methoxy-benzyl)-amine 454 Dibenzofuran-2-yl-(3 -phenoxy-benzyl)-amine 455 Dibenzofuran-2-yl-methyl(2-methyl-benzyl)-amine 456 Dibenzofuran-2-yl-( 1 -phenyl-butyl)-amine 457 Dibenzofuran-2-yl-phenethyl-amine 458 Dibenzofixran-2-yl-(l-phenyl-ethyl)-amine

Inventors: BOOTH RICHARD JOHN, JOSYULA VARA PRASAD VENKATA NA, MEYER ANNETTE LYNN, STEINBAUGH BRUCE ALLAN, BOOTH, RICHARD, JOHN, JOSYULA, VARA, PRASAD, VENKATA, NAGENDRA, MEYER, ANNETTE, LYNN, STEINBAUGH, BRUCE, ALLAN
Applicants: BOOTH RICHARD JOHN, JOSYULA VARA PRASAD VENKATA NA, MEYER ANNETTE LYNN, STEINBAUGH BRUCE ALLAN, WARNER LAMBERT CO, BOOTH, RICHARD, JOHN, JOSYULA, VARA, PRASAD, VENKATA, NAGENDRA, MEYER, ANNETTE, LYNN, STEINBAUGH, BRUCE, ALLAN, WARNER-LAMBERT COMPANY
Application year: 2000
Main classification: C07D307
IPC codes: A61K31, A61P31, C07C211, C07C215, C07C217, C07C317, C07D209, C07D211, C07D213, C07D215, C07D223, C07D279, C07D307, C07D319, C07D327, C07D333, C07D335, C07D401, C07D405, C07D407, C07D409, C07D411, C07D417, C07D491, C07D497